1
|
Lin X, Hu J, Zhou B, Wang X, Zhang Q, Jiang Y, Wang O, Xia W, Xing X, Li M. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study. J Clin Endocrinol Metab 2024; 109:1873-1882. [PMID: 38181430 PMCID: PMC11180512 DOI: 10.1210/clinem/dgae012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 12/12/2023] [Accepted: 01/05/2024] [Indexed: 01/07/2024]
Abstract
CONTEXT The comparative effectiveness of denosumab and zoledronic acid for adult patients with osteogenesis imperfecta (OI) has not been established. OBJECTIVE To evaluate the efficacy and safety of denosumab and zoledronic acid in adult patients with OI. METHODS This was a prospective, open-label study. Patients were randomized to receive denosumab 60 mg every 6 months or zoledronic acid 5 mg once for 12 months. Pathogenic mutations of OI were identified by next-generation sequencing and confirmed by Sanger sequencing. Percentage changes in the areal bone mineral density (aBMD), trabecular bone score (TBS), and bone turnover biomarkers (BTMs) from baseline to 6 and 12 months of treatment, as well as safety, were evaluated. RESULTS A total of 51 adults with OI (denosumab: 25, zoledronic acid: 26) were included, of whom 49 patients had identified pathogenic mutations. At 12 months, aBMD at the lumbar spine and total hip significantly increased by 4.34% (P = .005) and 1.45% (P = .023) in the denosumab group and by 4.92% (P = .006) and 2.02% (P = .016) in the zoledronic acid group, respectively. TBS showed an increasing trend by 1.39% and 2.70% in denosumab and zoledronic acid groups, respectively. Serum levels of β-isomerized carboxy-telopeptide of type I collagen and alkaline phosphatase markedly decreased after denosumab treatment. Percentage changes in aBMD, TBS, and BTMs during the treatment were similar between the 2 groups. Patients with OI with milder phenotypes showed a significantly higher increase in the TBS after 12 months of denosumab treatment than those with more severe phenotypes (P = .030). During the study period, the denosumab group had fewer adverse events than the zoledronic acid group. CONCLUSION Denosumab effectively increases aBMD in adults with OI, with similar efficacy to zoledronic acid. Long-term and large-sample studies are needed to confirm the antifracture efficacy and safety of denosumab in adult patients with OI.
Collapse
Affiliation(s)
- Xiaoyun Lin
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Jing Hu
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Bingna Zhou
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Xiaojie Wang
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Qian Zhang
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Yan Jiang
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Ou Wang
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Weibo Xia
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Xiaoping Xing
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| | - Mei Li
- Department of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
| |
Collapse
|
2
|
Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos Int 2024:10.1007/s00198-024-07118-0. [PMID: 38733394 DOI: 10.1007/s00198-024-07118-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Accepted: 05/03/2024] [Indexed: 05/13/2024]
Abstract
Denosumab and bisphosphonates for primary osteoporosis are generally well-tolerated, but their comparative safety remains unclear. We aimed to explore the comparative safety of denosumab and bisphosphonates in primary osteoporosis. Databases such as PubMed and Google Scholar were searched for relevant peer-reviewed randomized controlled trials published in English (as of December 2023). Trials comparing adverse events (AE) between denosumab and bisphosphonates in patients with primary osteoporosis were investigated. Data were pooled using a fixed- or random-effects model to determine the risk ratios (RR) and 95% confidence intervals (CIs) for various AEs in patients treated with denosumab in comparison to patients treated with bisphosphonates. Eleven trials (5,545 patients; follow-up period: 12-24 months) were included in this meta-analysis. All trials had a risk of bias (e.g., reporting bias linked to secondary endpoints and selection bias linked to random allocation). In comparison to bisphosphonates, denosumab was significantly associated with less withdrawal due to AEs (RR = 0.49; 95% CI 0.34-0.71), more five-point major adverse cardiovascular events (RR = 2.05; 95% CI 1.03-4.09), more cardiovascular AEs (RR = 1.61; 95% CI 1.07-2.41), more infections (RR = 1.14; 95% CI 1.02-1.27), more upper respiratory tract infections (RR = 1.56; 95% CI 1.08-2.25), less vertebral fractures (RR = 0.54; 95% CI 0.31-0.93), and less abdominal pain (RR = 0.44;95% CI 0.22-0.87). We explored the comparative safety of denosumab and bisphosphonates for primary osteoporosis, some of which could be attributed to their beneficial effects. However, all trials had a risk of bias. Further investigations are required to confirm our results.
Collapse
Affiliation(s)
- Takaomi Kobayashi
- Department of Orthopaedic Surgery, Taku City Hospital, Saga, Japan.
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan.
- Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan.
- Department of Clinical Research, Amagi Chuo Hospital, Fukuoka, Japan.
| | - Tadatsugu Morimoto
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| | - Koji Ito
- Department of Orthopaedic Surgery, Taku City Hospital, Saga, Japan
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| | - Masaaki Mawatari
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| | - Takafumi Shimazaki
- Department of Orthopaedic Surgery, Taku City Hospital, Saga, Japan
- Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan
| |
Collapse
|
3
|
Cosman F, Langdahl B, Leder BZ. Treatment Sequence for Osteoporosis. Endocr Pract 2024; 30:490-496. [PMID: 38311211 DOI: 10.1016/j.eprac.2024.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2023] [Revised: 01/22/2024] [Accepted: 01/26/2024] [Indexed: 02/10/2024]
Abstract
BACKGROUND Osteoporosis is a chronic progressive disease that requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach that can maximize benefits and avoid potential risks from long-term treatment with a single agent. OBJECTIVE This article reviews clinical trial data in postmenopausal women that evaluate the effects of antiresorptive agents followed by other antiresorptives, osteoanabolic agents followed by antiresorptives, and antiresorptives followed by osteoanabolic medications. METHODS Literature review and discussion. RESULTS When medications are discontinued, in the absence of sequential therapy, bone turnover rates return to baseline or above baseline, and bone loss occurs. The rate of bone loss differs for different treatments, with a very slow decline after stopping bisphosphonates and a particularly rapid decline after stopping denosumab. Careful attention to osteoporosis medication transitions can mitigate bone density loss and its consequences. For women who remain at high risk, switching from bisphosphonates to the more potent antiresorptive, denosumab, will result in further improvement in bone mineral density (BMD). When indicated, stopping denosumab can be accomplished safely by transition to an adequate bisphosphonate regimen. For high- and very-high-risk patients, treating with osteoanabolic agents first, followed by antiresorptive agents, produces substantially larger BMD gains than the reverse treatment sequence, with the biggest differences seen for BMD of the hip. CONCLUSION Awareness of the importance of treatment sequences can help improve osteoporosis care across the postmenopausal lifespan.
Collapse
Affiliation(s)
- Felicia Cosman
- Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York.
| | - Bente Langdahl
- Department of Endocrinology and Metabolic Bone Diseases, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
| | - Benjamin Z Leder
- Department of Medicine, Harvard Medical School, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
| |
Collapse
|
4
|
Lee DO, Hong YH, Cho MK, Choi YS, Chun S, Chung YJ, Hong SH, Hwang KR, Kim J, Kim H, Lee DY, Lee SR, Park HT, Seo SK, Shin JH, Song JY, Yi KW, Paik H, Lee JY. The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part I. J Menopausal Med 2024; 30:1-23. [PMID: 38714490 PMCID: PMC11103071 DOI: 10.6118/jmm.24000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/19/2023] [Accepted: 01/20/2024] [Indexed: 05/10/2024] Open
Affiliation(s)
- Dong Ock Lee
- Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea
| | - Yeon Hee Hong
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
| | - Moon Kyoung Cho
- Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Korea
| | - Young Sik Choi
- Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Sungwook Chun
- Department of Obstetrics and Gynecology, Inje University Haeundae Paik Hospital, Busan, Korea
| | - Youn-Jee Chung
- Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Seung Hwa Hong
- Department of Obstetrics and Gynecology, Chungbuk National University Hospital, Cheongju, Korea
| | - Kyu Ri Hwang
- Department of Obstetrics and Gynecology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
| | - Jinju Kim
- Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea
| | - Hoon Kim
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
| | - Dong-Yun Lee
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Sa Ra Lee
- Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Hyun-Tae Park
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - Seok Kyo Seo
- Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| | - Jung-Ho Shin
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - Jae Yen Song
- Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Kyong Wook Yi
- Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Korea
| | - Haerin Paik
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
| | - Ji Young Lee
- Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul, Korea.
| |
Collapse
|
5
|
Son S, Oh MY, Yoo BR, Park HB. Comparison of the Efficacy of Zoledronate and Denosumab in Patients with Acute Osteoporotic Vertebral Compression Fractures: A Randomized Controlled Trial. J Clin Med 2024; 13:2040. [PMID: 38610804 PMCID: PMC11012809 DOI: 10.3390/jcm13072040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 03/26/2024] [Accepted: 03/28/2024] [Indexed: 04/14/2024] Open
Abstract
Background: The comparison of the efficacy of zoledronate and denosumab for treating osteoporosis is controversial, and few randomized controlled trials have compared these two drugs in practical patients with acute osteoporotic vertebral compression fractures (OVCFs). We conducted a randomized controlled study to compare the efficacy of zoledronate and denosumab in patients with acute OVCF, with a focus on the occurrence of new OVCF. Methods: We enrolled 206 subjects who had their first acute OVCF, without any previous history of osteoporosis medication. The patients were randomly assigned to receive either intravenous zoledronate once a year or subcutaneous denosumab twice a year. We investigated the OVCF recurrence, clinical outcome, bone mineral density (BMD), and bone turnover markers over 12 months. Results: The final cohort comprised 89 participants (mean age of 75.82 ± 9.34 years, including 74 women [83.15%]) in the zoledronate group and 86 patients (mean age of 75.53 ± 10.23 years, including 71 women [82.56%]) in the denosumab group. New OVCFs occurred in 8 patients (8.89%) in the zoledronate group and 11 patients (12.79%) in the denosumab group (odds ratio, 1.485 [95% confidence interval, 0.567-3.891], p = 0.419). No significant difference was observed in the survival analysis between the two groups (p = 0.407). The clinical outcome, including the visual analog scale score for pain and simple radiographic findings, did not differ between the two groups. The changes in BMD and bone turnover markers were also not significantly different between the two groups. Additionally, drug-related adverse events did not differ between the groups in terms of safety. Conclusions: The efficacy of zoledronate was comparable to that of denosumab in terms of the occurrence of new OVCFs, as well as of the overall clinical course in patients with their first acute OVCF. Notably, this study represents the first comparison of these two drugs in patients with acute OVCF. However, further research with large-scale and long-term follow-up is necessary.
Collapse
Affiliation(s)
- Seong Son
- Department of Neurosurgery, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea; (S.S.); (B.-R.Y.)
| | - Michael Y. Oh
- Department of Neurological Surgery, University of California, Irvine, CA 95064, USA
| | - Byung-Rhae Yoo
- Department of Neurosurgery, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea; (S.S.); (B.-R.Y.)
| | - Han-Byeol Park
- Department of Neurosurgery, Gil Medical Center, Gachon University College of Medicine, Incheon 21565, Republic of Korea; (S.S.); (B.-R.Y.)
| |
Collapse
|
6
|
Tai TW, Chen HY, Shih CA, Huang CF, McCloskey E, Lee JK, Yeap SS, Cheung CL, Charatcharoenwitthaya N, Jaisamrarn U, Kuptniratsaikul V, Yang RS, Lin SY, Taguchi A, Mori S, Li-Yu J, Ang SB, Chan DC, Chan WS, Ng H, Chen JF, Tu ST, Chuang HH, Chang YF, Chen FP, Tsai KS, Ebeling PR, Marin F, Nistal Rodríguez FJ, Shi H, Hwang KR, Kim KK, Chung YS, Reid IR, Chandran M, Ferrari S, Lewiecki EM, Hew FL, Ho-Pham LT, Nguyen TV, Nguyen VH, Lekamwasam S, Pandey D, Bhadada S, Chen CH, Hwang JS, Wu CH. Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporos Sarcopenia 2024; 10:3-10. [PMID: 38690538 PMCID: PMC11056428 DOI: 10.1016/j.afos.2024.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 02/09/2024] [Accepted: 02/17/2024] [Indexed: 05/02/2024] Open
Abstract
Objectives This study aimed to present the Asia-Pacific consensus on long-term and sequential therapy for osteoporosis, offering evidence-based recommendations for the effective management of this chronic condition. The primary focus is on achieving optimal fracture prevention through a comprehensive, individualized approach. Methods A panel of experts convened to develop consensus statements by synthesizing the current literature and leveraging clinical expertise. The review encompassed long-term anti-osteoporosis medication goals, first-line treatments for individuals at very high fracture risk, and the strategic integration of anabolic and antiresorptive agents in sequential therapy approaches. Results The panelists reached a consensus on 12 statements. Key recommendations included advocating for anabolic agents as the first-line treatment for individuals at very high fracture risk and transitioning to antiresorptive agents following the completion of anabolic therapy. Anabolic therapy remains an option for individuals experiencing new fractures or persistent high fracture risk despite antiresorptive treatment. In cases of inadequate response, the consensus recommended considering a switch to more potent medications. The consensus also addressed the management of medication-related complications, proposing alternatives instead of discontinuation of treatment. Conclusions This consensus provides a comprehensive, cost-effective strategy for fracture prevention with an emphasis on shared decision-making and the incorporation of country-specific case management systems, such as fracture liaison services. It serves as a valuable guide for healthcare professionals in the Asia-Pacific region, contributing to the ongoing evolution of osteoporosis management.
Collapse
Affiliation(s)
- Ta-Wei Tai
- Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Hsuan-Yu Chen
- Department of Orthopedic Surgery, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
| | - Chien-An Shih
- Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Chun-Feng Huang
- Division of Family Medicine, En Chu Kong Hospital, New Taipei City, Taiwan
- Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
- Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan
| | - Eugene McCloskey
- Division of Clinical Medicine, School of Medicine and Population Health, Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing (CIMA), University of Sheffield, Sheffield, UK
| | - Joon-Kiong Lee
- Department of Orthopaedics, Beacon Hospital, Petaling Jaya, Selangor, Malaysia
| | - Swan Sim Yeap
- Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Ching-Lung Cheung
- Department of Pharmacology and Pharmacy, Centre for Genomic Sciences, The University of Hong Kong, Pokfulam, Hong Kong
| | | | - Unnop Jaisamrarn
- Center of Excellence in Menopause and Aging Women Health, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Vilai Kuptniratsaikul
- Department of Rehabilitation Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Rong-Sen Yang
- Department of Orthopedic Surgery, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
| | - Sung-Yen Lin
- Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
- Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Akira Taguchi
- Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Nagano, Japan
- Department of Hard Tissue Research, Graduate School of Oral Medicine, Matsumoto Dental University, Nagano, Japan
| | - Satoshi Mori
- Bone and Joint Surgery, Seirei Hamamatsu General Hospital, Shizuoka, Japan
| | - Julie Li-Yu
- Department of Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines
| | - Seng Bin Ang
- Menopause Unit and Family Medicine Service, KK Women's and Children's Hospital, Singapore
| | - Ding-Cheng Chan
- Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Wai Sin Chan
- Department of Internal Medicine Orthopaedics, Centro Hospitalar Conde de Sao Januario, Macao, China
| | - Hou Ng
- Department of Internal Medicine, Centro Hospitalar Conde de Sao Januario, Macau, China
| | - Jung-Fu Chen
- Division of Metabolism and Endocrinology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Shih-Te Tu
- Division of Endocrinology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
| | - Hai-Hua Chuang
- Department of Family Medicine, Taipei and Linkou Main Branches, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Metabolism and Obesity Institute, Taipei and Linkou Main Branches, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Department of Industrial Engineering and Management, National Taipei University of Technology, Taipei, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Yin-Fan Chang
- Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Fang-Ping Chen
- Department of Obstetrics and Gynecology, Osteoporosis Prevention and Treatment Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
- Department of Medicine, College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan
| | - Keh-Sung Tsai
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Peter R. Ebeling
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Fernando Marin
- Department of Endocrinology, Hospital Universitario Quironsalud, Madrid, Spain
- Medical Sciences School, Universidad Europea, Madrid, Spain
| | | | - Huipeng Shi
- National Center for Orthopedics, Department of Orthooedics, Shanghai 6th People's Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Kyu Ri Hwang
- Department of Obstetrics & Gynecology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea
| | - Kwang-Kyoun Kim
- Department of Orthopedic Surgery, Konyang University College of Medicine, Daejeon, Republic of Korea
| | - Yoon-Sok Chung
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea
| | - Ian R. Reid
- Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
| | - Manju Chandran
- Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore
| | - Serge Ferrari
- Service of Bone Diseases, Department of Medicine, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland
| | - E Michael Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
| | - Fen Lee Hew
- Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Lan T. Ho-Pham
- BioMedical Research Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam
| | - Tuan Van Nguyen
- Tâm Anh Research Institute, Ho Chi Minh City, Viet Nam
- School of Population Health, UNSW Medicine, UNSW Sydney, Australia
- Centre for Health Technologies, University of Technology Sydney (UTS), Sydney, Australia
| | - Van Hy Nguyen
- Orthopaedic Center, Hue Central Hospital, Hue City, Viet Nam
| | - Sarath Lekamwasam
- Department of Medicine, Faculty of Medicine, University of Ruhuna, Sri Lanka
| | | | | | - Chung-Hwan Chen
- Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
- Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Orthopedics, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Department of Orthopedics, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
- Ph.D. Program in Biomedical Engineering, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan
- Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, Taiwan
- Graduate Institute of Materials Engineering, College of Engineering, National Pingtung University of Science and Technology, Pingtung, Taiwan
| | - Jawl-Shan Hwang
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan
| | - Chih-Hsing Wu
- Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- Department of Family Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- Institute of Gerontology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| |
Collapse
|
7
|
Han YX, Mo YY, Wu HX, Iqbal J, Cai JM, Li L, Bu YH, Xiao F, Jiang HL, Wen Y, Zhou HD. Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine 2024; 68:102425. [PMID: 38312239 PMCID: PMC10835219 DOI: 10.1016/j.eclinm.2024.102425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 01/04/2024] [Accepted: 01/04/2024] [Indexed: 02/06/2024] Open
Abstract
Background The sequential anti-osteoporotic treatment for women with postmenopausal osteoporosis (PMO) is important, but the order in which different types of drugs are used is confusing and controversial. Therefore, we performed a network meta-analysis to compare the efficacy and safety of available sequential treatments to explore the most efficacious strategy for long-term management of osteoporosis. Methods In this network meta-analysis, we searched the PubMed, EMBASE, Web of Science, the Cochrane Library, and ClinicalTrials.gov from inception to September 19, 2023 to identify randomised controlled trials comparing sequential treatments for women with PMO. The identified trials were screened by reading the title and abstract, and only randomised clinical trials involving sequential anti-osteoporotic treatments and reported relevant outcomes for PMO were included. The main outcomes included vertebral fracture risk, the percentage change in bone mineral density (BMD) in different body parts, and all safety indicators in the stage after switching treatment. A frequentist network meta-analysis was performed using the multivariate random effects method and evaluated using the surface under the cumulative ranking curve (SUCRA). Certainty of evidence was assessed using the Confidence in the Network Meta-Analysis (CINeMA) framework. This study is registered with PROSPERO: CRD42022360236. Findings A total of 19 trials comprising 18,416 participants were included in the study. Five different sequential treatments were investigated as the main interventions and compared to the corresponding control groups. The intervention groups in this study comprised the following treatment switch protocols: switching from an anabolic agent (AB) to an anti-resorptive agent (AR) (ABtAR), transitioning from one AR to another AR (ARtAAR), shifting from an AR to an AB (ARtAB), switching from an AB to a combined treatment of AB and AR (ABtC), and transitioning from an AR to a combined treatment (ARtC). A significant reduction in the incidence of vertebral fractures was observed in ARtC, ABtAR and ARtAB in the second stage, and ARtC had the lowest incidence with 81.5% SUCRA. ARtAAR and ABtAR were two effective strategies for preventing fractures and improving BMD in other body parts. Especially, ARtAAR could improve total hip BMD with the highest 96.1% SUCRA, and ABtAR could decrease the risk of total fractures with the highest 94.3% SUCRA. Almost no difference was observed in safety outcomes in other comparisons. Interpretation Our findings suggested that the ARtAAR and ABtAR strategy are the effective and safe sequential treatment for preventing fracture and improving BMD for PMO. ARtC is more effective in preventing vertebral fractures. Funding The National Natural Science Foundation of China (82170900, 81970762), the Hunan Administration of Traditional Chinese Medicine, and the Hunan Province High-level Health Talents "225" Project.
Collapse
Affiliation(s)
- Yu-Xin Han
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Yu-Yao Mo
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Hui-Xuan Wu
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Junaid Iqbal
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Jun-Min Cai
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Long Li
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Yan-Hong Bu
- Department of Blood Transfusion, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Fen Xiao
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Hong-Li Jiang
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Ying Wen
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Hou-De Zhou
- National Clinical Research Centre for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| |
Collapse
|
8
|
Bekas KN, Zafeiris C. The Role of Bone Mineral Density in a Successful Lumbar Interbody Fusion: A Narrative Review. Cureus 2024; 16:e54727. [PMID: 38524011 PMCID: PMC10960932 DOI: 10.7759/cureus.54727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/22/2024] [Indexed: 03/26/2024] Open
Abstract
BACKGROUND The incidence of osteoporosis is a prime concern, especially in parts of the world where the population is aging, such as Europe or the US. Many new therapy strategies have been described to enhance bone healing. Lumbar interbody fusion (LIF) is a surgical procedure that aims to stabilize the lumbar spine by fusing two or more vertebrae using an interbody cage. LIF is a standard treatment for various spinal conditions, such as degenerative disc disease, spinal stenosis, and spondylolisthesis. However, successful fusion is challenging for patients with osteoporosis due to their reduced bone mineral density (BMD) and increased risk of cage subsidence, which can lead to implant failure and poor clinical outcomes. METHODS A comprehensive literature search yielded 220 articles, with 16 ultimately included. Keywords included BMD, cage subsidence, osteoporosis, teriparatide, and lumbar interbody fusion. RESULTS This review examines the relationship between BMD and LIF success, emphasizing the importance of adequate bone quality for successful fusion. Preoperative assessment methods for BMD and the impact of low BMD on fusion rates and patient outcomes are discussed. Additionally, techniques to improve fusion success in patients with weakened bone density, such as biological enhancement and BMD-matched interbody cages, are explored. However, consensus on the exact BMD threshold for a successful outcome remains elusive. CONCLUSION While an apparent correlation between BMD and fusion rate in LIF procedures is acknowledged, conclusive evidence regarding the precise BMD threshold indicative of an increased risk of unfavorable outcomes remains elusive. Surgeons are advised to exercise caution in surgical planning and follow-up for patients with lower BMD. Furthermore, future research initiatives, particularly longitudinal studies, are encouraged to prioritize the examination of BMD as a fundamental risk factor, addressing gaps in the literature.
Collapse
Affiliation(s)
- Kyriakos N Bekas
- Orthopaedics, 1st Orthopaedics Department, G. Gennimatas General Hospital, Athens, GRC
- Th. Garofalidis Laboratory for Research of the Musculoskeletal System, Medical School, National and Kapodistrian University of Athens, Athens, GRC
| | - Christos Zafeiris
- Th. Garofalidis Laboratory for Research of the Musculoskeletal System, Medical School, National and Kapodistrian University of Athens, Athens, GRC
- Orthopaedics and Spine Surgery, Metropolitan General Hospital, Athens, GRC
| |
Collapse
|
9
|
Ramchand SK, Leder BZ. Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis. J Clin Endocrinol Metab 2024; 109:303-311. [PMID: 37610985 DOI: 10.1210/clinem/dgad496] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/03/2023] [Accepted: 08/21/2023] [Indexed: 08/25/2023]
Abstract
Osteoporosis is a chronic condition characterized by decreased bone mass, loss of skeletal integrity, and increased susceptibility to fracture. Drugs used to treat osteoporosis can be classified as those that block bone resorption (antiresorptive), stimulate bone formation (anabolic), or do both. While all currently approved medications reduce the risk of fragility fractures in high-risk populations, they are generally unable to fully restore bone strength in most patients with established disease. Thus, the majority of patients require disease management over many years. Unfortunately, the continuous use of a single drug has limitations, both in terms of efficacy and safety, and so sequential therapy is commonly required. Given the expanding list of pharmacological agents currently available, careful consideration needs to be given as to which drugs to use and in what sequence. This review will evaluate the differential effects of antiresorptive, bone-forming, and dual-acting drugs when used in specific sequences and will explore the current evidence favoring the initial use of bone-forming/dual-acting drugs followed by antiresorptive medications. This review will also examine the notion that long-term treatment with an antiresorptive drug may diminish the efficacy of subsequent treatment with a bone-forming/dual-acting drug. Finally, this review will explore the current evidence pertaining to the specific issue of how to best prevent the clinical ramifications of denosumab cessation.
Collapse
Affiliation(s)
- Sabashini K Ramchand
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA 02114, USA
| | - Benjamin Z Leder
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA 02114, USA
| |
Collapse
|
10
|
Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, Santesso N, Ridout R, Ward W, Ashe MC, Bardai Z, Bartley J, Binkley N, Burrell S, Butt D, Cadarette SM, Cheung AM, Chilibeck P, Dunn S, Falk J, Frame H, Gittings W, Hayes K, Holmes C, Ioannidis G, Jaglal SB, Josse R, Khan AA, McIntyre V, Nash L, Negm A, Papaioannou A, Ponzano M, Rodrigues IB, Thabane L, Thomas CA, Tile L, Wark JD. Actualisation 2023 des lignes directrices de pratique clinique pour la prise en charge de l’ostéoporose et la prévention des fractures au Canada. CMAJ 2023; 195:E1585-E1603. [PMID: 38011931 PMCID: PMC10681677 DOI: 10.1503/cmaj.221647-f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2023] Open
Abstract
Contexte: Au Canada, plus de 2 millions de personnes vivent avec l’ostéoporose, une maladie qui accroît le risque de fracture, ce qui fait augmenter la morbidité et la mortalité, et entraîne une perte de qualité de vie et d’autonomie. La présente actualisation des lignes directrices vise à accompagner les professionnelles et professionnels de la santé au Canada dans la prestation de soins visant à optimiser la santé osseuse et à prévenir les fractures chez les femmes ménopausées et les hommes de 50 ans et plus. Méthodes: Le présent document fournit une actualisation des lignes directrices de pratique clinique de 2010 d’Ostéoporose Canada sur le diagnostic et la prise en charge de l’ostéoporose au pays. Nous avons utilisé l’approche GRADE (Grading of Recommendations Assessment, Development and Evaluation) et effectué l’assurance de la qualité conformément aux normes de qualité et de présentation des rapports de la grille AGREE II (Appraisal of Guidelines for Research & Evaluation). Les médecins de premier recours et les patientes et patients partenaires ont été représentés à tous les niveaux des comités et des groupes ayant participé à l’élaboration des lignes directrices, et ont participé à toutes les étapes du processus pour garantir la pertinence des informations pour les futurs utilisateurs et utilisatrices. Le processus de gestion des intérêts concurrents a été entamé avant l’élaboration des lignes directrices et s’est poursuivi sur toute sa durée, selon les principes du Réseau international en matière de lignes directrices. Dans la formulation des recommandations, nous avons tenu compte des avantages et des risques, des valeurs et préférences de la patientèle, des ressources, de l’équité, de l’acceptabilité et de la faisabilité; la force de chacune des recommandations a été déterminée en fonction du cadre GRADE. Recommandations: Les 25 recommandations et les 10 énoncés de bonne pratique sont répartis en sections : activité physique, alimentation, évaluation du risque de fracture, instauration du traitement, interventions pharmacologiques, durée et séquence du traitement, et monitorage. La prise en charge de l’ostéoporose devrait se fonder sur le risque de fracture, établi au moyen d’une évaluation clinique réalisée avec un outil d’évaluation du risque de fracture validé. L’activité physique, l’alimentation et la pharmacothérapie sont des éléments essentiels à la stratégie de prévention des fractures, qui devraient être personnalisés. Interprétation: Les présentes lignes directrices ont pour but d’outiller les professionnelles et professionnels de la santé et la patientèle afin qu’ensemble ils puissent parler de l’importance de la santé osseuse et du risque de fracture tout au long de la vie adulte avancée. La détection et la prise en charge efficace de la fragilité osseuse peuvent contribuer à réduire les fractures et à préserver la mobilité, l’autonomie et la qualité de vie.
Collapse
Affiliation(s)
- Suzanne N Morin
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Sidney Feldman
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Larry Funnell
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Lora Giangregorio
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Sandra Kim
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Heather McDonald-Blumer
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Nancy Santesso
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Rowena Ridout
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Wendy Ward
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Maureen C Ashe
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Zahra Bardai
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Joan Bartley
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Neil Binkley
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Steven Burrell
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Debra Butt
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Suzanne M Cadarette
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Angela M Cheung
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Phil Chilibeck
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Sheila Dunn
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Jamie Falk
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Heather Frame
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - William Gittings
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Kaleen Hayes
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Carol Holmes
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - George Ioannidis
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Susan B Jaglal
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Robert Josse
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Aliya A Khan
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Virginia McIntyre
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Lynn Nash
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Ahmed Negm
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Alexandra Papaioannou
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Matteo Ponzano
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Isabel B Rodrigues
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Lehana Thabane
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Christine A Thomas
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - Lianne Tile
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| | - John D Wark
- Université McGill (Morin), Montréal, Qc; Université de Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patientes et patients partenaires (Funnell, McIntyre, Bartley, Thomas); Université de Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Université Brock (Ward, Gittings), St. Catharines, Ont.; Université McMaster (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; Université du Wisconsin (Binkley), Madison, Wisc.; Université Dalhousie (Burrell], Halifax, N.-É.; Centre médical Menzies (Holmes), Morden, Man.; Université de Calgary (Negm), Calgary, Alb.; Université de la Colombie-Britannique (Ashe), Vancouver, C.-B.; Université de la Saskatchewan (Chilibeck), Saskatoon, Sask.; Université de la Colombie-Britannique (Ponzano), Kelowna, C.-B.; Université de Melbourne (Wark), Melbourne, Australie; Université du Manitoba (Falk, Frame), Winnipeg, Man.; Université Brown (Hayes), Providence, R.I
| |
Collapse
|
11
|
Calaf-Alsina J, Cano A, Guañabens N, Palacios S, Cancelo MJ, Castelo-Branco C, Larrainzar-Garijo R, Neyro JL, Nogues X, Diez-Perez A. Sequential management of postmenopausal health and osteoporosis: An update. Maturitas 2023; 177:107846. [PMID: 37738717 DOI: 10.1016/j.maturitas.2023.107846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 07/24/2023] [Accepted: 09/01/2023] [Indexed: 09/24/2023]
Abstract
Increased life expectancy means that women are now in a hypoestrogenic state for approximately one-third of their lives. Overall health and specifically bone health during this period evolves in accordance with aging and successive exposure to various risk factors. In this review, we provide a summary of the approaches to the sequential management of osteoporosis within an integrative model of care to offer physicians a useful tool to facilitate therapeutic decision-making. Current evidence suggests that pharmacologic agents should be selected based on the risk of fractures, which does not always correlate with age. Due to their effect on bone turnover and on other hormone-regulated phenomena, such as hot flushes or breast cancer risk, we position hormone therapy and selective estrogen receptor modulators as an early postmenopause intervention for the management of postmenopausal osteoporosis. When the use of these agents is not possible, compelling evidence supports antiresorptive agents as first-line treatment of postmenopausal osteoporosis in many clinical scenarios, with digestive conditions, kidney function, readiness for compliance, or patient preferences playing a role in choosing between bisphosphonates or denosumab during this period. For patients at high risk of osteoporotic fracture, the "anabolic first" approach reduces that risk. The effect on bone health with these bone-forming agents or with denosumab should be consolidated with the subsequent use of antiresorptive agents. Regardless of the strategy, follow-up and treatment should be maintained indefinitely to help prevent fractures.
Collapse
Affiliation(s)
- Joaquin Calaf-Alsina
- Obstetrics and Gynaecology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma Barcelona, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain.
| | - Antonio Cano
- Pediatrics, Obstetrics and Gynecology Department, University of Valencia - INCLIVA, Avd. de Menéndez y Pelayo 4, 46010, Valencia, Spain.
| | - Núria Guañabens
- Rheumatology Department, Hospital Clinic, IDIBAPS, University of Barcelona, C. de Villarroel 170, 08036 Barcelona, Spain.
| | - Santiago Palacios
- Institute Palacios of Woman's Health, C. de Antonio Acuña 9, 28009 Madrid, Spain.
| | - M Jesús Cancelo
- Obstetrics and Gynecology Department, Hospital Universitario de Guadalajara, C. Donante de Sangre S/N, 19002 Guadalajara, Spain.
| | - Camil Castelo-Branco
- Gynecology Department, Clinical Institute of Gynecology, Obstetrics & Neonatology, Hospital Clínic Barcelona, Universitat de Barcelona, C. de Villarroel, 170, 08036 Barcelona, Spain.
| | - Ricardo Larrainzar-Garijo
- Orthopaedics and Trauma Department, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, 28031 Madrid, Spain.
| | - José Luis Neyro
- Obstetrics and Gynaecology Department, Hospital Universitario Cruces, Cruces Plaza, s/n, 48903-Barakaldo, Bilbao, Spain
| | - Xavier Nogues
- Internal Medicine Department, IMIM (Hospital del Mar Medical Research Institute), Pompeu Fabra University, CIBERFES (Frailty and Healthy Aging Research Network), Instituto Carlos III, Passeig Maritim 25-29, 08003 Barcelona, Spain.
| | - Adolfo Diez-Perez
- Internal Medicine Department, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, Spain.
| |
Collapse
|
12
|
Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, Santesso N, Ridout R, Ward W, Ashe MC, Bardai Z, Bartley J, Binkley N, Burrell S, Butt D, Cadarette SM, Cheung AM, Chilibeck P, Dunn S, Falk J, Frame H, Gittings W, Hayes K, Holmes C, Ioannidis G, Jaglal SB, Josse R, Khan AA, McIntyre V, Nash L, Negm A, Papaioannou A, Ponzano M, Rodrigues IB, Thabane L, Thomas CA, Tile L, Wark JD. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ 2023; 195:E1333-E1348. [PMID: 37816527 PMCID: PMC10610956 DOI: 10.1503/cmaj.221647] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/12/2023] Open
Abstract
BACKGROUND In Canada, more than 2 million people live with osteoporosis, a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life and loss of autonomy. This guideline update is intended to assist Canadian health care professionals in the delivery of care to optimize skeletal health and prevent fractures in postmenopausal females and in males aged 50 years and older. METHODS This guideline is an update of the 2010 Osteoporosis Canada clinical practice guideline on the diagnosis and management of osteoporosis in Canada. We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework and quality assurance as per Appraisal of Guidelines for Research and Evaluation (AGREE II) quality and reporting standards. Primary care physicians and patient partners were represented at all levels of the guideline committees and groups, and participated throughout the entire process to ensure relevance to target users. The process for managing competing interests was developed before and continued throughout the guideline development, informed by the Guideline International Network principles. We considered benefits and harms, patient values and preferences, resources, equity, acceptability and feasibility when developing recommendations; the strength of each recommendation was assigned according to the GRADE framework. RECOMMENDATIONS The 25 recommendations and 10 good practice statements are grouped under the sections of exercise, nutrition, fracture risk assessment and treatment initiation, pharmacologic interventions, duration and sequence of therapy, and monitoring. The management of osteoporosis should be guided by the patient's risk of fracture, based on clinical assessment and using a validated fracture risk assessment tool. Exercise, nutrition and pharmacotherapy are key elements of the management strategy for fracture prevention and should be individualized. INTERPRETATION The aim of this guideline is to empower health care professionals and patients to have meaningful discussions on the importance of skeletal health and fracture risk throughout older adulthood. Identification and appropriate management of skeletal fragility can reduce fractures, and preserve mobility, autonomy and quality of life.
Collapse
Affiliation(s)
- Suzanne N Morin
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI.
| | - Sidney Feldman
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Larry Funnell
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Lora Giangregorio
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Sandra Kim
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Heather McDonald-Blumer
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Nancy Santesso
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Rowena Ridout
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Wendy Ward
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Maureen C Ashe
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Zahra Bardai
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Joan Bartley
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Neil Binkley
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Steven Burrell
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Debra Butt
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Suzanne M Cadarette
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Angela M Cheung
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Phil Chilibeck
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Sheila Dunn
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Jamie Falk
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Heather Frame
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - William Gittings
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Kaleen Hayes
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Carol Holmes
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - George Ioannidis
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Susan B Jaglal
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Robert Josse
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Aliya A Khan
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Virginia McIntyre
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Lynn Nash
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Ahmed Negm
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Alexandra Papaioannou
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Matteo Ponzano
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Isabel B Rodrigues
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Lehana Thabane
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Christine A Thomas
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - Lianne Tile
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| | - John D Wark
- McGill University (Morin), Montréal, Que.; University of Toronto (Feldman, Kim, McDonald-Blumer, Ridout, Cheung, Josse, Tile, Bardai, Butt, Cadarette, Dunn, Jaglal), Toronto, Ont.; patient partners (Funnell, McIntyre, Bartley, Thomas); University of Waterloo (Giangregorio, Kim, McLaughlin, Rodrigues), Waterloo, Ont.; Brock University (Ward, Gittings), St. Catharines, Ont.; McMaster University (Santesso, Ioannidis, Khan, Nash, Thabane, Papaioannou), Hamilton, Ont.; University of Wisconsin (Binkley), Madison, Wisc.; Dalhousie University (Burrell), Halifax, NS; Menzies Medical Centre (Holmes), Morden, Man.; University of Calgary (Negm), Calgary, Alta.; University of British Columbia (Ashe), Vancouver, BC; University of Saskatchewan (Chilibeck), Saskatoon, Sask.; University of British Columbia (Ponzano), Kelowna, BC; University of Melbourne (Wark), Melbourne, Australia; University of Manitoba (Falk, Frame), Winnipeg, Man.; Brown University (Hayes), Providence, RI
| |
Collapse
|
13
|
Foessl I, Dimai HP, Obermayer-Pietsch B. Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol 2023; 19:520-533. [PMID: 37464088 DOI: 10.1038/s41574-023-00866-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/21/2023] [Indexed: 07/20/2023]
Abstract
Osteoporosis is a skeletal disorder that causes impairment of bone structure and strength, leading to a progressively increased risk of fragility fractures. The global prevalence of osteoporosis is increasing in the ageing population. Owing to the chronic character of osteoporosis, years or even decades of preventive measures or therapy are required. The long-term use of bone-specific pharmacological treatment options, including antiresorptive and/or osteoanabolic approaches, has raised concerns around adverse effects or potential rebound phenomena after treatment discontinuation. Imaging options, risk scores and the assessment of bone turnover during initiation and monitoring of such therapies could help to inform individualized treatment strategies. Combination therapies are currently used less often than 'sequential' treatments. However, all patients with osteoporosis, including those with secondary and rare causes of osteoporosis, as well as specific patient populations (for example, young adults, men and pregnant women) require new approaches for long-term therapy and disease monitoring. New pathophysiological aspects of bone metabolism might therefore help to inform and revolutionize the diagnosis and treatment of osteoporosis.
Collapse
Affiliation(s)
- Ines Foessl
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University Graz, Graz, Austria
| | - Hans P Dimai
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University Graz, Graz, Austria
| | - Barbara Obermayer-Pietsch
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
| |
Collapse
|
14
|
Okuno F, Ito-Masui A, Hane A, Maeyama K, Ikejiri K, Ishikura K, Yanagisawa M, Dohi K, Suzuki K. Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report. Int J Emerg Med 2023; 16:52. [PMID: 37635211 PMCID: PMC10463425 DOI: 10.1186/s12245-023-00529-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 08/20/2023] [Indexed: 08/29/2023] Open
Abstract
BACKGROUND Severe hypocalcemia may lead to life-threatening arrhythmias. Denosumab is an effective treatment for osteoporosis that allows long intervals between doses. However, there is a risk of hypocalcemia in some patients. Due to the long half-life of denosumab, emergency physicians caring for patients presenting with symptoms of hypocalcemia may not be aware of the medication, and adverse effects may last longer. CASE PRESENTATION A 55-year-old woman with a history of systemic lupus erythematosus (SLE) and anxiety disorder called for an ambulance for symptoms of hyperventilation and muscle cramps. After evaluation at the local hospital, she developed pulseless ventricular tachycardia and was resuscitated by defibrillation by the hospital staff. After conversion to sinus rhythm, she was transported to a tertiary center. Upon arrival, pulseless ventricular tachycardia occurred again, and veno-arterial extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pumping (IABP) were implemented. Laboratory results showed severe hypocalcemia (corrected calcium level of 5.3 mg/dL) whereupon intravenous calcium supplementation was started. She had received the first dose of denosumab (60 mg) by subcutaneous injection 24 days prior to hospitalization. She was eventually weaned from ECMO and IABP support. CONCLUSION Cardiac arrest due to hypocalcemia is relatively rare but can be fatal. In the present case, hyperventilation may have acutely exacerbated pre-existing hypocalcemia, leading to ventricular tachycardia. The patient had a slightly decreased serum calcium level prior to denosumab. Close monitoring may be preferable after the primary dose of denosumab in selected patients. Emergency physicians caring for patients who may be suffering from symptoms/signs of hypocalcemia must be mindful of medications that have long half-lives and affect electrolyte balance when treating fatal arrhythmia due to hypocalcemia.
Collapse
Affiliation(s)
- Fumito Okuno
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Asami Ito-Masui
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan.
| | - Atsuya Hane
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Keiko Maeyama
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Kaoru Ikejiri
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Ken Ishikura
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Masashi Yanagisawa
- Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Kaoru Dohi
- Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| | - Kei Suzuki
- Emergency and Critical Care Center, Mie University Hospital, 2-174 Edobashi, Tsu-City, Mie, 514-8507, Japan
| |
Collapse
|
15
|
Tian L, Luo C, Li YF, Wang QY, Qu XL, Yue C, Xu LL, Yang YY, Sheng ZF. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. Arch Osteoporos 2023; 18:100. [PMID: 37460858 DOI: 10.1007/s11657-023-01309-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Accepted: 07/06/2023] [Indexed: 07/20/2023]
Abstract
Postmenopausal patients with osteoporosis who have a recent fracture are at very high risk of fracture, and this study finds that stratified treatment based on fracture risk would be a cost-effective treatment option for this population. PURPOSE To evaluate the cost-effectiveness of four anti-osteoporosis medications (denosumab, zoledronate, teriparatide, and alendronate) for postmenopausal osteoporotic women in mainland China, using a stratified treatment strategy recommended by the American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE). METHODS A microsimulation Markov model was used to compare the cost-effectiveness of the four treatments in postmenopausal osteoporotic patients of different ages (65, 70, 75, and 80 years), with a recent fracture from the Chinese healthcare perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER), which represent the incremental cost per quality-adjusted life-year (QALY) obtained. One-way deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) were performed to assess the robustness of model findings. RESULTS Alendronate was dominated by denosumab-to-alendronate and zoledronate at all ages examined, indicating that the costs of the two drugs were lower, but QALYs was greater. However, teriparatide-to-alendronate yielded an ICER of $76,432.07/ QALY, compared with alendronate at age 65, which exceeded the pre-determined willingness-to-pay threshold of $37,653/ QALY. The results were similar at other ages. The DSA showed that the most sensitive parameters were drug efficacy for vertebral and wrist fractures, the relative risk of vertebral fractures, and the persistence of the drugs. The PSA showed that zoledronate had a 100% probability of being the most cost-effective treatment, with a willingness-to-pay threshold of $37,653/ QALY. CONCLUSION Stratified treatment based on very high fracture risk is more cost-effective than conventional pills in mainland China. Among the stratified treatments, zoledronate is the optimal option.
Collapse
Affiliation(s)
- Lin Tian
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Chuo Luo
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Yong-Fang Li
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Qin-Yi Wang
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Xiao-Li Qu
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Chun Yue
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China
| | - Lu-Lu Xu
- Health Management Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Yan-Yi Yang
- Health Management Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
| | - Zhi-Feng Sheng
- Health Management Center, National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, Hunan, 410011, China.
| |
Collapse
|
16
|
Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, Christensen R, Body JJ, Brandi ML, Diez-Perez A, Hadji P, Javaid MK, Lems WF, Nogues X, Roux C, Minisola S, Kurth A, Thomas T, Prieto-Alhambra D, Ferrari SL, Langdahl B, Abrahamsen B. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 2023; 381:e068033. [PMID: 37130601 PMCID: PMC10152340 DOI: 10.1136/bmj-2021-068033] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
OBJECTIVE To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. DESIGN Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. DATA SOURCES Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. RESULTS The results were based on 69 trials (>80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. CONCLUSIONS The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42019128391.
Collapse
Affiliation(s)
- Mina Nicole Händel
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Department of Clinical Research, Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark
| | - Isabel Cardoso
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Cecilie von Bülow
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Occupational Science, User Perspectives and Community-Based Interventions, Department of Public Health, University of Southern Denmark, Odense C, Denmark
| | - Jeanett Friis Rohde
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Anja Ussing
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Sabrina Mai Nielsen
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
| | - Robin Christensen
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
| | - Jean-Jacques Body
- Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Adolfo Diez-Perez
- Department of Internal Medicine, Institut Hospital del Mar of Medical Investigation, Autonomous University of Barcelona and CIBERFES (Frailty and Healthy Aging Research Network), Instituto Carlos III, Barcelona, Spain
| | - Peyman Hadji
- Frankfurt Centre of Bone Health, Frankfurt and Philipps-University of Marburg, Marburg, Germany
| | - Muhammad Kassim Javaid
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | | | - Xavier Nogues
- IMIM (Hospital del Mar Medical Research Institute), Parc de Salut Mar, Pompeu Fabra University, Barcelona, Spain
| | - Christian Roux
- INSERM U 1153, Hospital Paris-Centre, University of Paris, Paris, France
| | - Salvatore Minisola
- Department of Clinical, Internal, Anaesthesiologic, and Cardiovascular Sciences, Rome University, Rome, Italy
| | - Andreas Kurth
- Department of Orthopaedic and Trauma Surgery, Marienhaus Klinikum Mainz, Major Teaching Hospital, University Medicine Mainz, Mainz, Germany
| | - Thierry Thomas
- Université Jean Monnet Saint-Étienne, CHU de Saint-Etienne, Rheumatology Department, INSERM U1059, F-42023, Saint-Etienne, France
| | - Daniel Prieto-Alhambra
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | | | - Bente Langdahl
- Departments of Clinical Medicine and of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark
| | - Bo Abrahamsen
- Department of Clinical Research, Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- Department of Medicine, Holbæk Hospital, Holbæk, Denmark
| |
Collapse
|
17
|
Moshi MR, Nicolopoulos K, Stringer D, Ma N, Jenal M, Vreugdenburg T. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcif Tissue Int 2023; 112:631-646. [PMID: 37016189 DOI: 10.1007/s00223-023-01078-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 12/24/2022] [Indexed: 04/06/2023]
Abstract
To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW). Systematic searches were run in PubMed, Embase & Cochrane Library on 27-April-2022. Randomized controlled trials (RCTs) that included osteoporotic PMW allocated to denosumab, SERMs, bisphosphonates, or placebo were eligible for inclusion. RCTs were appraised using Cochrane Risk of Bias 2.0. Bayesian network and/or pairwise meta-analyses were conducted on predetermined outcomes (i.e. vertebral/nonvertebral fractures, bone mineral density [BMD], mortality, adverse events [AEs], serious AEs (SAEs), withdrawals due to AEs, AEs caused by denosumab discontinuation). A total of 12 RCTs (k = 22 publications; n = 25,879 participants) were included in the analyses. Denosumab, reported a statistically significant increase in lumbar spine (LS) and total hip (TH) BMD, compared to placebo. Similarly, denosumab also resulted in a statistically significant increase in TH BMD compared to the raloxifene and bazedoxifene. However, relative to denosumab, alendronate, ibandronate and risedronate resulted in significant improvements in both femoral neck (FN) and LS BMD. With regards to vertebral fractures and all safety outcomes, there were no statistically significant differences between denosumab and any of the comparator. Relative to placebo, denosumab was associated with significant benefits in both LS and TH BMD. Additionally, denosumab (compared to placebo) was not associated with reductions in vertebral and nonvertebral fractures. Finally, denosumab was not associated with improvement in safety outcomes, compared to placebo. These findings should be interpreted with caution as some analyses suffered from statistical imprecision.
Collapse
Affiliation(s)
- Magdalena Ruth Moshi
- Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, 24 King William Street, Kent Town, South Australia, 5067, Australia.
| | - Konstance Nicolopoulos
- Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, 24 King William Street, Kent Town, South Australia, 5067, Australia
| | - Danielle Stringer
- Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, 24 King William Street, Kent Town, South Australia, 5067, Australia
| | - Ning Ma
- Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, 24 King William Street, Kent Town, South Australia, 5067, Australia
| | - Mathias Jenal
- Health Technology Assessment Section, Health Insurance Benefits Division, Health and Accident Insurance Directorate, Federal Office of Public Health (FOPH), Bern, Switzerland
| | - Thomas Vreugdenburg
- Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of Surgeons, 24 King William Street, Kent Town, South Australia, 5067, Australia
| |
Collapse
|
18
|
Belaya Z, Rozhinskaya L, Dedov I, Drapkina O, Fadeev V, Golounina O, Lesnyak O, Mamedova E, Melnichenko G, Petraikin A, Rodionova S, Skripnikova I, Tkacheva O, Toroptsova N, Yureneva S, Kanis JA. A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. Osteoporos Int 2023; 34:429-447. [PMID: 36651943 DOI: 10.1007/s00198-022-06667-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 12/29/2022] [Indexed: 01/19/2023]
Abstract
UNLABELLED Key statements of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis are summarized. They were developed by a task force representing the key Russian professional associations involved in the management of osteoporosis and approved by the Russian Ministry of Health. PURPOSE To summarize key statements of the Russian clinical practice guidelines for the diagnosis and treatment of osteoporosis. METHODS The Russian clinical guidelines on the diagnosis and treatment of osteoporosis were developed by a task force representing the key Russian professional associations involved in the management of osteoporosis: These comprised the Russian Association of Endocrinologists, the Russian Association for Osteoporosis, the Association of Rheumatologists of Russia, the Association of Orthopedic surgeons and Traumatologists of Russia, the Russian Association of Gynecologists-Endocrinologists, and the Russian Association of Gerontologists and Geriatrics. The guidelines are based on a systematic literature review and principles of evidence-based medicine and were compiled in accordance with the requirements for clinical recommendations developed by the Ministry of Health of the Russian Federation. RESULTS Key statements included in the Russian guidelines of osteoporosis approved by the Russian Ministry of Health in 2021 are summarized. The statements are graded based on levels of evidence and supported by short comments. The guidelines are focused on the current approach to screening, diagnosis, differential diagnosis, and treatment of osteoporosis. CONCLUSION These guidelines are a practical tool for general practitioners, as well as medical specialists, primarily endocrinologists, rheumatologists, orthopedic surgeons, and other physicians who are involved in the management of patients with osteoporosis.
Collapse
Affiliation(s)
- Zhanna Belaya
- Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia.
| | - Liudmila Rozhinskaya
- Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia
| | - Ivan Dedov
- Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia
| | - Oksana Drapkina
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Valentin Fadeev
- Department of Endocrinology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - Olga Golounina
- Department of Endocrinology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
| | - Olga Lesnyak
- Family Medicine Department-Western State Medical University Named After I.I. Mechnikov, St. Petersburg, Russia
| | - Elizaveta Mamedova
- Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia
| | - Galina Melnichenko
- Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia
| | - Alexey Petraikin
- Department of Radiation Diagnostics, Research and Practical Clinical Center for Diagnostics, Telemedicine Technologies of Moscow Health Care Department, Moscow, Russia
| | - Svetlana Rodionova
- National Medical Research Center of Traumatology and Orthopedics named after. N.N. Priorov, Moscow, Russia
| | - Irina Skripnikova
- National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
| | - Olga Tkacheva
- Russian National Research Medical University Named After N.I. Pirogov, Moscow, Russia
| | | | - Svetlana Yureneva
- Department of Gynecological Endocrinology, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After V.I. Kulakov, Moscow, Russia
| | - John A Kanis
- Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
- Center for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
| |
Collapse
|
19
|
Li X, Han J, Shi X, Bi Z, Liu J. Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 2023; 18:37. [PMID: 36840811 DOI: 10.1007/s11657-023-01227-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Accepted: 02/10/2023] [Indexed: 02/26/2023]
Abstract
OBJECTIVE Periprosthetic bone mineral density (BMD) loss after total hip arthroplasty (THA) may threaten the survival of implants. Zoledronic acid (ZA) and denosumab were effective in reducing bone loss in conditions associated with accelerated bone turnover by inhibiting osteoclast activity. This meta-analysis aimed to assess the efficiency and safety of ZA and denosumab for periprosthetic BMD loss after THA. METHODS A systematic search of randomized controlled trials (RCTs) associated with ZA or denosumab and THA was performed in MEDLINE, PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the Web of Science from 1980 to 2022. Meta-analysis was performed by the Cochrane Review Manager 5 (RevMan) version 5.41. Cochrane risk of bias tool and GRADEpro were applied for methodological quality and overall evidence quality, respectively. RESULTS Nine RCTs involving a total of 480 patients were finally included and analyzed. The pooled data that demonstrated significantly less periprosthetic BMD loss in Gruen zone 7 occurred in the intervention group patients than in the control group patients at 3 months (MD = 4.30, 95% CI: 1.78-6.82, P = 0.0008), 6 months (MD = 7.71, 95% CI: 5.41-10.02, P < 0.00001), and 12 months (MD = 8.19, 95% CI: 5.97-10.42, P < 0.00001) after THA. No serious adverse events (AEs) were observed. CONCLUSION In the current analysis with evidence on the efficacy and safety of ZA and denosumab, the authors recommend the use of ZA or denosumab treatment for periprosthetic bone mineral density loss. SYSTEMATIC REVIEW REGISTRATION PROSPERO registration number: CRD42022369273.
Collapse
Affiliation(s)
- Xiao Li
- Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, China
| | - Jingru Han
- Department of Oncology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xiaotong Shi
- Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, China
| | - Zhiguo Bi
- Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, China
| | - Jianguo Liu
- Department of Orthopedics, First Hospital of Jilin University, Changchun, Jilin, China.
| |
Collapse
|
20
|
Dai S, Du Y, Chen L, Xu Y, Hu Q. A mid- and long-term follow-up study on the bilateral pedicle anchoring technique with percutaneous vertebroplasty for the treatment of Kümmell's disease. Front Surg 2023; 10:1061498. [PMID: 36778647 PMCID: PMC9909088 DOI: 10.3389/fsurg.2023.1061498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 01/03/2023] [Indexed: 01/27/2023] Open
Abstract
Study design Retrospective study of clinical and radiological parameters. Objective To investigate the clinical efficacy and long-term stability of bone cement of the bilateral pedicle anchoring technique with percutaneous vertebroplasty (PVP) in the treatment of Kümmell's disease (KD). Summary of background data The optimal treatment regimen for KD remains controversial. With the development of minimally invasive orthopedic techniques, PVP has been widely recognized for its advantages, such as less surgical trauma, shorter operation time, less blood loss, quick recovery, and pain relief. Previous reports indicate that in patients who undergo PVP for KD, bone cement may be displaced, causing pain recurrence, or it may enter the spinal canal and cause spinal cord compression, especially in the long term. Theoretically, the bilateral pedicle anchoring technique can enhance the stability of the bone cement in the vertebral body and reduce the occurrence of long-term bone cement displacement. However, there are few reports on the use of this technique to treat KD. This study reports the mid- and long-term follow-up of the clinical and radiological outcomes of the bilateral pedicle anchoring technique with PVP for the treatment of KD. Methods From January 2016 to January 2019, 41 patients with KD treated using the bilateral pedicle anchoring technique with PVP in our hospital were enrolled. There were 10 men and 31 women with an average age of 76.5 ± 8.0 years (range: 55-92 years). The average follow-up duration was 19.3 ± 8.0 months (range: 12-38 months). Visual analog scale (VAS) scores, Oswestry disability index (ODI), anterior vertebral height, kyphotic angle, and wedge angle were recorded before surgery, 1 day after surgery, and at the last follow-up. Clinical efficacy, vertebral height recovery, and bone cement displacement were analyzed in combination using plain radiographs, computed tomography, magnetic resonance imaging, and other imaging data. Results All the patients successfully underwent the procedure without serious complications. No obvious displacement of bone cement was found in the imaging data obtained 1 day after the operation and at the last follow-up. VAS scores, ODI scores, anterior vertebral height, kyphotic angle, and wedge angle of the injured vertebrae significantly improved after surgery. There was no significant difference between the anterior vertebral height, kyphotic angle, and wedge angle of the vertebral body obtained 1 day after surgery and those obtained at the last follow-up. Bone cement leakage occurred in seven patients, with no abnormal clinical symptoms. Conclusion The bilateral pedicle anchoring technique with PVP integrates the use of bone cement in both the vertebral body and the bone cement in the pedicle, enhances the stability of the bone cement, and effectively prevents the displacement of the intravertebral bone cement. The postoperative bone cement stability was high, the clinical effect was obvious, and the long-term follow-up results were satisfactory. Hence, this is a safe and effective surgical method for the treatment of KD.
Collapse
Affiliation(s)
- Shichang Dai
- Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yu Du
- Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China,Correspondence: Yu Du
| | - Liang Chen
- Department of Bone and Soft Tissue Oncology, Chongqing University Cancer Hospital, Chongqing, China
| | - Yifan Xu
- Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Qiong Hu
- Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| |
Collapse
|
21
|
Ramchand SK, David NL, Lee H, Bruce M, Bouxsein ML, Tsai JN, Leder BZ. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension. J Bone Miner Res 2023; 38:26-34. [PMID: 36333954 PMCID: PMC10098948 DOI: 10.1002/jbmr.4737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/12/2022] [Accepted: 11/01/2022] [Indexed: 11/06/2022]
Abstract
The combination of denosumab and teriparatide is an effective treatment strategy in postmenopausal osteoporosis, though skeletal gains are promptly lost when these agents are discontinued. In the DATA-HD study, we reported that a single dose of zoledronic acid (ZOL) maintains the increases in areal spine and hip bone mineral density (BMD) achieved with this combination for at least 12 months. The capacity of ZOL to maintain corresponding improvements in peripheral volumetric BMD and microarchitecture, however, has not been reported. In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9). In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose. We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42. Despite ZOL administration, total and cortical BMD gradually decreased over 27 months resulting in values similar to baseline at the radius but still significantly above baseline at the tibia. At both sites, cortical porosity decreased to values below pretreatment baseline at month 27 but then increased from month 27 to 42. There were no significant changes in trabecular parameters throughout the 27-month post-ZOL observation period. Stiffness and failure load, at both sites, decreased progressively from month 15 42 though remained above baseline at the tibia. These findings suggest that in contrast to the largely maintained gains in dual-energy X-ray absorptiometry (DXA)-derived spine and hip BMD, a single dose of ZOL was not as effective in maintaining the gains in volumetric peripheral bone density and microarchitecture produced by 15 months of overlapping treatment with denosumab and teriparatide. Alternative therapeutic approaches that can fully maintain improvements in peripheral bone parameters require further study. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Collapse
Affiliation(s)
- Sabashini K Ramchand
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.,Department of Medicine, Endocrine Unit, Austin Hospital, The University of Melbourne, Victoria, Australia
| | - Natalie L David
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | - Hang Lee
- Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA
| | - Michael Bruce
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | - Mary L Bouxsein
- Department of Orthopedic Surgery, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
| | - Joy N Tsai
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA
| | - Benjamin Z Leder
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA
| |
Collapse
|
22
|
Guo J, Zhang N, Cheng Y. Comparative efficacy of medicaments or techniques for pulpotomy of primary molars: a network meta-analysis. Clin Oral Investig 2023; 27:91-104. [PMID: 36580161 PMCID: PMC9876877 DOI: 10.1007/s00784-022-04830-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Accepted: 12/18/2022] [Indexed: 12/30/2022]
Abstract
OBJECTIVES We performed this network meta-analysis to determine the comparative efficacy of formocresol (FC), ferric sulfate (FS), sodium hypochlorite (NaOCl), calcium hydroxide (CH), mineral trioxide aggregate (MTA), biodentine, and laser for pulpotomy of molar teeth. MATERIALS AND METHODS An updated search was conducted in PubMed, Embase, and the Cochrane Library to identify relevant randomized controlled trials (RCTs) published before October 30, 2022, after screening previous meta-analyses. The Cochrane risk of bias assessment tool was used to appraise the methodological quality of included studies. Clinical and radiographic success rates were assessed as outcomes. Random network meta-analysis was performed by using STATA software (version 14.0) with "network" command. RESULTS A total of 43 RCTs were included. Network meta-analysis indicated that CH was inferior to other medicaments and techniques in all outcomes, and MTA and biodentine was better than FC, FS, and NaOCl in terms of clinical and radiographic success rates. Results of ranking probabilities suggested that MTA ranked first in all outcomes except for clinical success at both 6 months. CONCLUSIONS Our results suggested that MTA was associated with significant improvement in both clinical and radiographic success than other pulpotomy medicaments and techniques, with the highest probability of being the optimal option. CLINICAL RELEVANCE The current network meta-analysis determined the comparative efficacy and safety of 7 common pulpotomy medicaments in molar pulpotomy, including FC, FS, NaOCl, CH, MTA, biodentine, and laser, and the pooled results revealed comparable efficacy in clinical and radiographic success rates at 6 and 12 months between FC, FS, and NaOCl in primary molars pulpotomies. However, MTA, biodentine and laser may have more advantages than other pulpotomy medicaments for clinical and radiographic success. Therefore, in clinical practice, practitioners should select MTA, biodentine, or laser as pulpotomy medicaments in molar pulpotomy.
Collapse
Affiliation(s)
- Jiehua Guo
- Department of Oral Medicine, Shanxi Provincial People's Hospital, NO.29 The Twin Towers Temple District, Taiyuan, Shanxi, China.
| | - Na Zhang
- Department of Oral Medicine, Shanxi Provincial People's Hospital, NO.29 The Twin Towers Temple District, Taiyuan, Shanxi, China
| | - Yuzhao Cheng
- Department of Oral Medicine, Shanxi Provincial People's Hospital, NO.29 The Twin Towers Temple District, Taiyuan, Shanxi, China
| |
Collapse
|
23
|
Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev 2022; 44:417-473. [PMID: 36510335 PMCID: PMC10166271 DOI: 10.1210/endrev/bnac031] [Citation(s) in RCA: 36] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2022] [Revised: 11/26/2022] [Accepted: 12/05/2022] [Indexed: 12/15/2022]
Abstract
Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the last 20 years, much experience has been gained in measurement and interpretation of these markers, which include commonly used bone formation markers bone alkaline phosphatase, osteocalcin, and procollagen I N-propeptide; and commonly used resorption markers serum C-telopeptides of type I collagen, urinary N-telopeptides of type I collagen and tartrate resistant acid phosphatase type 5b. BTMs are usually measured by enzyme-linked immunosorbent assay or automated immunoassay. Sources contributing to BTM variability include uncontrollable components (e.g., age, gender, ethnicity) and controllable components, particularly relating to collection conditions (e.g., fasting/feeding state, and timing relative to circadian rhythms, menstrual cycling, and exercise). Pregnancy, season, drugs, and recent fracture(s) can also affect BTMs. BTMs correlate with other methods of assessing bone turnover, such as bone biopsies and radiotracer kinetics; and can usefully contribute to diagnosis and management of several diseases such as osteoporosis, osteomalacia, Paget's disease, fibrous dysplasia, hypophosphatasia, primary hyperparathyroidism, and chronic kidney disease-mineral bone disorder.
Collapse
Affiliation(s)
- Marian Schini
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.,Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Tatiane Vilaca
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - Fatma Gossiel
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - Syazrah Salam
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.,Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Richard Eastell
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| |
Collapse
|
24
|
Psimma C, Psimma Z, Willems HC, Klüter WJ, van der Maarel‐Wierink CD. Oral bisphosphonates: Adverse effects on the oral mucosa not related to the jaw bones. A scoping review. Gerodontology 2022; 39:330-338. [PMID: 34725854 PMCID: PMC9787882 DOI: 10.1111/ger.12590] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/12/2021] [Accepted: 09/14/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND Oral bisphosphonates are widely used in the treatment of bone resorptive diseases. There is an evidence that oral bisphosphonates can exert adverse effects on the oral mucosa independently of their effects on the jaw bones. OBJECTIVE To systematically map the literature on adverse effects of oral bisphosphonates on the oral mucosa of adults with bone resorptive diseases. DESIGN Scoping review of the literature, including different study designs. METHODS Systematic searches of the PubMed, LILACS, Google Scholar and EMBASE databases were conducted. Two independent reviewers screened titles and abstracts according to predetermined criteria. RESULTS The search retrieved 26 unique articles, comprising 22 case reports, one case series and three reviews describing a total of 56 cases of oral adverse events related to oral bisphosphonates. 88% of the reported cases were female suffering from comorbidities other than metabolic bone diseases. The improper use of the oral bisphosphonate was the most suspected cause of the adverse effect on the oral mucosa. Its management mainly involved withdrawal of the medication. CONCLUSION Adverse effects on the oral mucosa can develop from using oral bisphosphonates. Standardised registration of these adverse effects in university clinics and private practises could provide additional information about their occurrence and severity.
Collapse
Affiliation(s)
- Christina Psimma
- BT‐AcademyCenter for Special Care in Dentistry AmsterdamAmsterdamThe Netherlands
| | - Zoi Psimma
- Private PracticeZoetermeerThe Netherlands
| | - Hanna C. Willems
- Department Internal Medicine, Section GeriatricsAmsterdam UMCAmsterdamThe Netherlands
| | - Wim J. Klüter
- BENECOMOFlemish‐Netherlands Geriatric Oral Research GroupNijmegenThe Netherlands,College of Dental SciencesRadboud University Medical CentreNijmegenThe Netherlands
| | - Claar D. van der Maarel‐Wierink
- BT‐AcademyCenter for Special Care in Dentistry AmsterdamAmsterdamThe Netherlands,BENECOMOFlemish‐Netherlands Geriatric Oral Research GroupNijmegenThe Netherlands,College of Dental SciencesRadboud University Medical CentreNijmegenThe Netherlands,Department of Oral MedicineAcademic Centre for Dentistry AmsterdamAmsterdamThe Netherlands
| |
Collapse
|
25
|
Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2022; 66:724-738. [PMID: 36382762 PMCID: PMC10118820 DOI: 10.20945/2359-3997000000564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
It is now well recognized that over the lifetime of a patient with osteoporosis, more than one medication will be needed to treat the disease and to decrease fracture risk. Though current gaps in osteoporosis therapy can be potentially mitigated with sequential and combination regimens, how to move seamlessly amongst the multiple treatments currently available for osteoporosis for sustained efficacy is still unclear. Data from recent studies show that an anabolic agent such as teriparatide or romosozumab followed by an antiresorptive affords maximal gain in BMD and possibly better and earlier fracture risk reduction compared to a regimen which follows the opposite sequence. Sequentially moving to a bisphosphonate such as alendronate from an anabolic agent such as abaloparatide has also been shown to preserve the fracture reduction benefits seen with the latter. This sequence of an anabolic agent followed by an antiresorptive should especially be considered in the high-risk patient with imminent fracture risk to rapidly reduce the risk of subsequent fractures. The data surrounding optimum timing of initiation of bisphosphonate therapy following denosumab discontinuation is still unclear. Though data suggests that combining a bisphosphonate with teriparatide does not provide substantial BMD gains compared to monotherapy, the concomitant administration of denosumab with teriparatide has been shown to significantly increase areal BMD as well as to increase volumetric BMD and estimated bone strength. This narrative review explores the available evidence regarding the various sequential and combination therapy approaches and the potential role they could play in better managing osteoporosis.
Collapse
|
26
|
Al-Toma A, Herman A, Lems WF, Mulder CJJ. The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance. Nutrients 2022; 14:4554. [PMID: 36364816 PMCID: PMC9654202 DOI: 10.3390/nu14214554] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Revised: 10/14/2022] [Accepted: 10/26/2022] [Indexed: 12/08/2023] Open
Abstract
Impaired bone mineral density (BMD) is a frequent complication of adult-onset celiac disease (CeD). This is usually due to malabsorption of nutrients, changes in bone metabolism in association with inflammation, and to a lesser extent, decreased overall physical health and mobility. This review aims to highlight the current status concerning surveillance, prevention, and treatment strategies for bone disease in CeD. A practical guidance on these matters is suggested. The available published research on the prevention and treatment of decreased BMD in relation to CeD is scarce. In general, publications were based on expert opinions or extrapolation from studies on postmenopausal women or inflammatory bowel disease. Optimal dietary treatment and an adequate supply of calcium and vitamin D are the cornerstones for the reduction in fracture risk in patients with CeD. In adults with low BMD or fragility fractures, CeD needs to be considered and specifically approached. When osteoporosis is documented, start treatment with an antiresorptive agent; these agents are proven to result in a long-term reduction in fracture risk in high-risk individuals. However, there are some important differences between the management of male and female patients, particularly premenopausal women, that need to be addressed. In patients with persisting diarrhea and malabsorption, parenteral medications may be preferable. Future research specifically focusing on celiac disease and the associated disorders in bone mineralization is mandatory to provide evidence-based recommendations in this field.
Collapse
Affiliation(s)
- Abdulbaqi Al-Toma
- Department of Gastroenterology and Hepatology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
| | - Amin Herman
- Department of Rheumatology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands
| | - Willem F. Lems
- Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands
| | - Chris J. J. Mulder
- Department of Gastroenterology, Amsterdam UMC, Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands
| |
Collapse
|
27
|
Critical illness and bone metabolism: where are we now and what is next? Eur J Med Res 2022; 27:177. [PMID: 36104724 PMCID: PMC9472372 DOI: 10.1186/s40001-022-00805-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 09/02/2022] [Indexed: 11/10/2022] Open
Abstract
AbstractCritical illness refers to the clinical signs of severe, variable and life-threatening critical conditions, often accompanied by insufficiency or failure of one or more organs. Bone health of critically ill patients is severely affected during and after ICU admission. Therefore, clinical work should focus on ICU-related bone loss, and early development and implementation of related prevention and treatment strategies: optimized and personalized nutritional support (high-quality protein, trace elements and intestinal prebiotics) and appropriate physiotherapy and muscle training should be implemented as early as possible after ICU admission and discharge. At the same time, the drug regulates excessive metabolism and resists osteoporosis.
Collapse
|
28
|
Everts‐Graber J, Bonel H, Lehmann D, Gahl B, Häuselmann H, Studer U, Ziswiler H, Reichenbach S, Lehmann T. Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy – a Registry‐based Cohort Study. JBMR Plus 2022; 6:e10681. [PMID: 36248270 PMCID: PMC9549725 DOI: 10.1002/jbm4.10681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 09/01/2022] [Indexed: 11/17/2022] Open
Abstract
Atypical femoral fractures (AFFs) have been reported in patients taking bisphosphonates (BPs) for osteoporosis therapy but also in patients with no exposure to these drugs. In contrast, less is known about the incidence of AFFs in patients taking denosumab. This registry‐based cohort study analyzed the incidence of AFFs in patients with suspected or confirmed osteoporosis who were included in the osteoporosis register of the Swiss Society of Rheumatology between January 2015 and September 2019. Statistical analyses included incidence rates, rate ratios, and hazard ratios for AFFs, and considered sequential therapies and drug holidays as time‐dependent covariates. Among the 9956 subjects in the cohort, 53 had subtrochanteric or femoral shaft fractures. Ten fractures occurred under BP or denosumab treatment and two under teriparatide therapy. Five fractures were classified as AFFs based on the revised American Society of Bone and Mineral Research case definition of AFFs from 2014. Three AFFs occurred in women being treated with denosumab at the time of diagnosis, all with prior BP use (10, 7, and 1 years, respectively). One AFF developed in a woman receiving ibandronate and one arose in a woman receiving glucocorticoids rather than antiresorptive therapy. The incidence of AFFs per 10,000 observed patient‐years was 7.1 in patients receiving denosumab and 0.9 in patients with BP‐associated AFFs, yielding a rate ratio of 7.9 (95% confidence interval [CI] 0.63–413), p = 0.073. The risk of AFFs was not significantly higher in patients receiving denosumab therapy compared with BP therapy (hazard ratio = 7.07, 95% CI 0.74–68.01, p = 0.090). We conclude that the risk of AFFs is low in patients taking BPs, denosumab, or both sequentially. All three patients with AFFs under denosumab therapy had undergone prior BP therapy. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Judith Everts‐Graber
- OsteoRheuma Bern, Bahnhofplatz 1 Bern Switzerland
- Department of Rheumatology and Immunology, Inselspital, Bern University Hospital University of Bern Switzerland
| | - Harald Bonel
- Campus Stiftung Lindenhof Bern Swiss Institute for Translational and Entrepreneurial Medicine Bern Switzerland
- Department of Radiology Lindenhof Hospital Bern Switzerland
- Department of Radiology, Inselspital University of Bern Switzerland
| | | | | | - HansJörg Häuselmann
- Zentrum für Rheuma‐ und Knochenerkrankungen, Klinik Im Park, Hirslanden Zürich Switzerland
| | - Ueli Studer
- OsteoRheuma Bern, Bahnhofplatz 1 Bern Switzerland
| | | | - Stephan Reichenbach
- Department of Rheumatology and Immunology, Inselspital, Bern University Hospital University of Bern Switzerland
- Institute for Social and Preventive Medicine University of Bern Switzerland
| | | |
Collapse
|
29
|
Kong SH. Denosumab, an effective osteoporosis treatment option for men. Korean J Intern Med 2022; 37:947-948. [PMID: 36068715 PMCID: PMC9449201 DOI: 10.3904/kjim.2022.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Accepted: 08/12/2022] [Indexed: 11/30/2022] Open
Affiliation(s)
- Sung Hye Kong
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- Correspondence to Sung Hye Kong, M.D. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumiro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel: +82-31-787-8126 Fax: +82-31-787-7029 E-mail:
| |
Collapse
|
30
|
Jeong C, Ha J, Kim J, Lim Y, Kim MK, Kwon HS, Song KH, Kang MI, Baek KH. The efficacy of denosumab in Korean male patients with osteoporosis. Korean J Intern Med 2022; 37:1011-1020. [PMID: 36068717 PMCID: PMC9449194 DOI: 10.3904/kjim.2022.064] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 03/30/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND/AIMS Despite the prominence of denosumab as the number one prescribed anti-osteoporosis drug in Korea, the effects of denosumab in male osteoporosis patients were not researched sufficiently. Moreover, concerns on rebound vertebral fractures associated with poor denosumab adherence exist. METHODS We retrospectively evaluated 147 Korean male osteoporosis patients treated with denosumab. After 12 months of treatment, 60 patients were lost during follow-up, and eight were excluded due to missing data. Out of the initial 147 patients, 79 were considered eligible for the analysis of the efficacy of denosumab. 54 patients were initially drug-naïve, and 25 had previously received bisphosphonate therapy. RESULTS In 54 drug-naïve patients, significant increases in bone mineral density (BMD) were observed in all measurement sites: 5.2% ± 3.7% in the lumbar spine, 2.3% ± 2.8% in the femoral neck, and 1.9% ± 2.8% in the total hip (p < 0.01, respectively). Trabecular bone score showed an increase of 0.5% ± 5.8% in drug-naïve patients. Likewise, in 25 patients with previous bisphosphonate treatment, increase in BMD were observed as well: 4.8% ± 3.5% in the lumbar spine, 1.4% ± 3.6% in the femoral neck, and 0.8% ± 2.1% in the total hip (p < 0.01, p = 0.06, p = 0.06, respectively). Significant declines of -55.1% ± 31.8% in C-terminal telopeptide of type 1 collagen (CTX), and -62.9% ± 21.3% in total procollagen 1 N-terminal propeptide (P1NP), in drug-naïve patients; and -37.7% ± 41.5%, in CTX and -55.4% ± 30.1%, in P1NP in patients with previous bisphosphonate treatment were exhibited after 12 months of treatment. The adherence rates of the second and third dosing schedules were 79.9% and 56.8%, respectively. CONCLUSION Our study indicates that denosumab is effective in increasing BMD in Korean osteoporosis males regardless of prior bisphosphonate treatment.
Collapse
Affiliation(s)
- Chaiho Jeong
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu,
Korea
| | - Jeonghoon Ha
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Jinyoung Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Yejee Lim
- Division of General Internal Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam,
Korea
| | - Mee Kyoung Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Hyuk-Sang Kwon
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Ki-Ho Song
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Moo Il Kang
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| | - Ki-Hyun Baek
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul,
Korea
| |
Collapse
|
31
|
Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone 2022; 162:116480. [PMID: 35787482 DOI: 10.1016/j.bone.2022.116480] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 06/27/2022] [Accepted: 06/27/2022] [Indexed: 11/22/2022]
Abstract
Romosozumab is a potent drug for treating postmenopausal osteoporosis but has a limited dosing period of 12 months. Bone mineral density (BMD) decreases soon after romosozumab discontinuation, thus emphasizing the importance of appropriate sequential treatment. The present VICTOR randomized controlled study compared the efficacy of ibandronate and denosumab as sequential therapy options following 12-month romosozumab treatment. Subjects completing 12 months of romosozumab administration for severe postmenopausal osteoporosis were randomly assigned to receive either ibandronate or denosumab for an additional 12 months. The primary outcome of interest was the percentage changes in BMD at the lumbar spine, total hip, and femoral neck from 12 months (completion of romosozumab) to 18 and 24 months of total treatment (6 and 12 months, respectively, after the conversion to sequential therapy). Secondary outcomes included alterations in serum bone turnover markers and the incidence of adverse events. Sixty-two subjects each in the ibandronate and denosumab groups completed the sequential therapy. The respective percentage changes in BMD at the lumbar spine from 12 months to 24 months were 2.5 % in the ibandronate group and 5.4 % in the denosumab group. At 24 months, we observed significant differences versus 12 months for both groups as well as between the groups (all P < 0.01), showing a superior ability to increase BMD at the lumbar spine for denosumab over ibandronate. BMD gains at the total hip and femoral neck exhibited comparably favorable trends. P1NP and TRACP-5b were significantly decreased from 12 to 24 months (-64.9 % and - 26.8 % in the ibandronate group and - 67.4 % and - 36.3 % in the denosumab group, respectively; all P < 0.001 versus 12 months). Several minor adverse events were recorded in both groups, none of which led to the discontinuation of the trial. The VICTOR study revealed that denosumab could be considered more effective than ibandronate, with few severe adverse events, for the enhancement of BMD as a sequential agent after romosozumab in postmenopausal osteoporosis patients.
Collapse
Affiliation(s)
- Tomonori Kobayakawa
- Kobayakawa Orthopedic and Rheumatologic Clinic, 1969 Kunou, Fukuroi, Shizuoka 437-0061, Japan
| | - Akiko Miyazaki
- Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Jun Takahashi
- Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
| | - Yukio Nakamura
- Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
| |
Collapse
|
32
|
Liang J, Chen J, Ye Z, Bao D. Cathelicidin LL-37 improves bone metabolic balance in rats with ovariectomy-induced osteoporosis via the Wnt/beta-catenin pathway. Physiol Res 2022; 71:369-377. [PMID: 35616038 DOI: 10.33549/physiolres.934820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Osteoporosis is a bone disease characterized by low bone mineral density (BMD) and impaired bone microarchitecture due to the abnormal activity of osteoclasts. Cathelicidins are antimicrobial peptides present in the lysosomes of macrophages and polymorphonuclear leukocytes. LL-37, a cathelicidin, induces various biological effects, including modulation of the immune system, angiogenesis, wound healing, cancer growth, as well as inflammation, and bone loss. A previous study reported direct involvement of LL-37 suppressing osteoclastogenesis in humans. Here, we examined the role of LL-37 in the treatment of osteoporosis using an ovariectomy (OVX) rat model. Our results showed that LL-37 significantly reduced bone loss and pathological injury in OVX rats with osteoporosis. Furthermore, we found that LL-37 significantly increased the activity of the Wnt/beta-catenin pathway in OVX rats with osteoporosis, including the increased expression of beta-catenin, Osterix (Osx), and Runt-related transcription factor 2 (Runx2), whereas XAV-939, an inhibitor of the Wnt/beta-catenin pathway, significantly blocked the effects of LL-37 on bone loss and abnormal bone metabolism. Altogether, our findings suggested that LL-37 exerted a protective role in regulating bone loss and abnormal bone metabolism in rats with osteoporosis by activating the Wnt/beta-catenin pathway.
Collapse
Affiliation(s)
- J Liang
- Department of Orthopedics, The First People's Hospital of Taizhou, Taizhou, China; Department of Pharmacy, The First People's Hospital of Taizhou, Taizhou, China.
| | | | | | | |
Collapse
|
33
|
Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. Arch Osteoporos 2022; 17:84. [PMID: 35715524 DOI: 10.1007/s11657-022-01129-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 06/07/2022] [Indexed: 02/03/2023]
Abstract
Denosumab is a newly approved treatment for osteoporosis in China. However, the clinical safety and advantages of denosumab have not been much established. The current study evaluates the real-world safety of denosumab versus zoledronic acid in treating cancer-free adults aged 50 years or older with osteoporosis to provide clinical settings guidelines. PURPOSE A head-to-head comparison of the safety profiles between denosumab (60 mg subcutaneously every 6 months) and zoledronic acid (5 mg, intravenously yearly) was performed in cancer-free adults aged 50 years or older with osteoporosis. METHODS MEDLINE, EMBASE, and Cochrane Library databases were searched for cohort studies comparing the safety of denosumab and zoledronic acid in cancer-free adults aged 50 years or older with osteoporosis till December 2021. The outcomes included the risk of fracture and other severe adverse events. Based on the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2, we identified the eligible studies. RESULTS Three cohort studies having 38,845 cancer-free adults aged 50 years or older were included in the study. The results showed that denosumab was not superior to zoledronic acid in reducing fracture risk [RR (95% CI): 1.05 (0.90, 1.23), P = 0.52]. However, denosumab had a low risk of composite cardiovascular disease [RR (95% CI): 0.82 (0.70, 0.96), P = 0.01]. There were no significant differences between the hazards of serious infection, and total adverse events (P > 0.05). CONCLUSION The present meta-analysis demonstrated that for cancer-free adults aged 50 years or older with osteoporosis, denosumab was as safe as zoledronic acid for the risk of drug-induced fractures. However, denosumab had a lower incidence of composite cardiovascular disease, and may be a better option for the population with cardiovascular disease. Nonetheless, due to limitations like a short-term follow-up, gender, and incomplete types of adverse effects, more randomized controlled trials (RCTs) are required to further verify this conclusion.
Collapse
|
34
|
Palmerini E, Pazzaglia L, Cevolani L, Pratelli L, Pierini M, Quattrini I, Carretta E, Manara MC, Pasello M, Frega G, Paioli A, Longhi A, Cesari M, Hakim R, Ibrahim T, Campanacci L, Staals EL, Donati DM, Benassi MS, Scotlandi K, Ferrari S. Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. Cancers (Basel) 2022; 14:cancers14122863. [PMID: 35740530 PMCID: PMC9220940 DOI: 10.3390/cancers14122863] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 05/30/2022] [Accepted: 06/07/2022] [Indexed: 02/01/2023] Open
Abstract
Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, is approved for GCTB. Data on serum bone turnover marker (sBTM) changes are lacking. We present a phase II correlative study on sBTMs in GCTB patients treated with denosumab. Methods: All GCTB patients receiving denosumab within a multicentre, open-label, phase 2 study were enrolled. Serum levels of carboxyterminal-crosslinked-telopeptide of type I collagen (s-CTX), alkaline phosphatase (ALP), bone-alkaline phosphatase (bALP), parathyroid hormone (sPTH), and osteocalcin (OCN) were prospectively assessed (baseline, T0, 3 months, T1, 6 months, T2). The primary endpoint was assessment of sBTM changes after denosumab; the secondary endpoints were disease-free survival (DFS) and sBTM correlation. Results: In 54 cases, sBTMs decreased during denosumab treatment except for sPTH. With a median follow-up of 59 months, 3-year DFS was 65% (%CI 52−79), with a significantly worse outcome for patients with high (≥500 UI/mL) s-CTX at baseline, as compared to low s-CTX (<500 UI/mL) (3-year DFS for high CTX 45% (95%CI 23−67) vs. 75% (95%CI 59−91) for low s-CTX. Higher median ALP and s-CTX were found for patients with tumor size ≥ 5 cm (p = 0.0512; p = 0.0589). Conclusion: Denosumab induces ALP/OCN and s-CTX reduction. High baseline s-CTX identifies a group of patients at higher risk of progression of the disease.
Collapse
Affiliation(s)
- Emanuela Palmerini
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
- Correspondence:
| | - Laura Pazzaglia
- SSD Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; (L.P.); (M.C.M.); (M.P.); (M.S.B.); (K.S.)
| | - Luca Cevolani
- Third Orthopaedic Clinic and Traumatology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (L.C.); (L.C.); (E.L.S.); (D.M.D.)
| | - Loredana Pratelli
- Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy;
| | - Michela Pierini
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Irene Quattrini
- Scientific Direction IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy;
| | - Elisa Carretta
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Maria Cristina Manara
- SSD Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; (L.P.); (M.C.M.); (M.P.); (M.S.B.); (K.S.)
| | - Michela Pasello
- SSD Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; (L.P.); (M.C.M.); (M.P.); (M.S.B.); (K.S.)
| | - Giorgio Frega
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Anna Paioli
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Alessandra Longhi
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Marilena Cesari
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Rossella Hakim
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Toni Ibrahim
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| | - Laura Campanacci
- Third Orthopaedic Clinic and Traumatology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (L.C.); (L.C.); (E.L.S.); (D.M.D.)
| | - Eric Lodewijk Staals
- Third Orthopaedic Clinic and Traumatology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (L.C.); (L.C.); (E.L.S.); (D.M.D.)
| | - Davide Maria Donati
- Third Orthopaedic Clinic and Traumatology, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (L.C.); (L.C.); (E.L.S.); (D.M.D.)
| | - Maria Serena Benassi
- SSD Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; (L.P.); (M.C.M.); (M.P.); (M.S.B.); (K.S.)
| | - Katia Scotlandi
- SSD Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; (L.P.); (M.C.M.); (M.P.); (M.S.B.); (K.S.)
| | - Stefano Ferrari
- Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapy, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy; (M.P.); (E.C.); (G.F.); (A.P.); (A.L.); (M.C.); (R.H.); (T.I.); (S.F.)
| |
Collapse
|
35
|
Cromer SJ, D'Silva KM, Yu EW, Landon J, Desai RJ, Kim SC. Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. J Gen Intern Med 2022; 37:1917-1924. [PMID: 34100235 PMCID: PMC9198174 DOI: 10.1007/s11606-021-06938-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 05/17/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND New bone-directed therapies, including denosumab, abaloparatide, and romosozumab, emerged during the past decade, and recent trends in use of these therapies are unknown. OBJECTIVE To examine temporal trends in bone-directed therapies. DESIGN An open cohort study in a US commercial insurance database, January 2009 to March 2020. PARTICIPANTS/INTERVENTIONS All-users of bone-directed therapies age >50 years, users with osteoporosis, users with malignancies, and patients with recent (within 180 days) fractures at key osteoporotic sites. MAIN MEASURES The percentage of each cohort with prescription dispensing or medication administration claims for each bone-directed therapy during each quarter of the study period. KEY RESULTS We analyzed 15.48 million prescription dispensings or medication administration claims from 1.46 million unique individuals (89% women, mean age 69 years). Among all users of bone-directed therapies, alendronate, and zoledronic acid use increased modestly (49 to 63% and 2 to 4%, respectively, during the study period). In contrast, denosumab use increased rapidly after approval in 2010, overtaking use of all other medications except alendronate by 2017 and reaching 16% of users by March 2020. Similar trends were seen in cohorts of osteoporosis, malignancy, and recent fractures. Importantly, use of any bone-directed therapy after fractures was low and declined from 15 to 8%. CONCLUSIONS Rates of denosumab use outpaced growth of all other bone-directed therapies over the past decade. Treatment rates after osteoporotic fractures were low and declined over time, highlighting major failings in osteoporosis treatment in the US.
Collapse
Affiliation(s)
- Sara Jane Cromer
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.,Division of Endocrinology, Diabetes, and Metabolism, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Kristin M D'Silva
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA.,Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA
| | - Elaine W Yu
- Division of Endocrinology, Diabetes, and Metabolism, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Joan Landon
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Rishi J Desai
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Seoyoung C Kim
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA. .,Harvard Medical School, Boston, MA, USA. .,Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
| |
Collapse
|
36
|
Effect of denosumab on renal function in women with osteoporosis evaluated using cystatin C. Osteoporos Sarcopenia 2022; 8:68-74. [PMID: 35832419 PMCID: PMC9263171 DOI: 10.1016/j.afos.2022.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 05/05/2022] [Accepted: 05/13/2022] [Indexed: 11/21/2022] Open
Abstract
Objectives To investigate renal function during denosumab therapy using the estimated glomerular filtration rate based on cystatin C (eGFRcys) which is more accurate than creatinine (eGFRcr) for renal function. Methods Bone mineral densities (BMDs) of lumbar spine and hip regions, eGFRcys, eGFRcr, creatinine clearance (Ccr), and serum total homocysteine (S-Hcy) were measured during 2-year denosumab therapy in 53 women with osteoporosis naïve to anti-osteoporosis drugs (new group) and 64 women who were switched from long-term bisphosphonate treatment to denosumab therapy (switch group). Results There were no significant differences in age, eGFRcr, Ccr, eGFRcys, and S-Hcy levels at baseline between the groups. BMDs in the lumbar spine, femoral neck, and total hip increased significantly after 2-year denosumab therapy in both groups. eGFRcr decreased in the switch group, and Ccr decreased in both groups; however, eGFRcys and S-Hcy levels did not change significantly in either group. To investigate the causal factors associated with the decrease in eGFRcr and Ccr, multiple regression analysis was performed in all patients. Denosumab initiation within 3 months after fracture and eGFRcr or Ccr at baseline were independent factors for the decrease in eGFRcr or Ccr during the 2-year denosumab therapy. Decline in creatinine-based renal function could be reflected by increased muscle mass during the ongoing recovery from fracture. Conclusions Renal function was preserved in all patients, including those in the switch group during denosumab therapy. Creatinine-based renal function should be cautiously interpreted during denosumab therapy in patients with recent fractures.
Collapse
|
37
|
Impact of Whole Body Vibration and Zoledronic Acid on Femoral Structure after Ovariectomy: Morphological Evaluation. J Clin Med 2022; 11:jcm11092441. [PMID: 35566566 PMCID: PMC9101134 DOI: 10.3390/jcm11092441] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 04/20/2022] [Accepted: 04/26/2022] [Indexed: 01/27/2023] Open
Abstract
Our study aimed to evaluate the effect of whole body vibration (WBV) treatment as an non-pharmacological method of treatment for early osteopenia in ovariectomized female rats. In total, 48 female Wistar rats were assigned to two groups: sham-operated control (SHAM, n = 12) and ovariectomized (n = 36). Four weeks after ovariectomy, the animals were divided into three experimental groups (n = 12 each): ovariectomized (OVX), ovariectomized subjected to whole body vibration with acceleration level of 0.3 g (OVX + WBV), or ovariectomized subjected to i.m. injection of Zoledronic acid at a dose of 0.025 mg/kg (OVX + ZOL). After the 8th and 16th week of treatment n = 6 rats from each group were euthanized and isolated femora were subjected to histological examination of trabecular bone and analysis of the expression of collagen 1 (Col1), osteoprotegerin (OPG), and receptor activator of nuclear factor kappa-Β ligand (RANKL) involved in bone turnover. The obtained results indicated that widespread vibration therapy can provide negative outcomes such as deterioration of trabecular bone histomorphometry.
Collapse
|
38
|
Kang T, Park SY, Lee SH, Park JH, Suh SW. Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS). J Korean Med Sci 2022; 37:e68. [PMID: 35380023 PMCID: PMC8980365 DOI: 10.3346/jkms.2022.37.e68] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 01/25/2022] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Denosumab (DEN) and zoledronic acid (ZOL) currently represent the most potent antiresorptive agents for the treatment of osteoporosis. Despite similar effects on bone resorption, these agents have distinct mechanisms of action. The objective of this study was to compare the effect of DEN and ZOL after two-year administration on bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers, and persistence. METHODS A total of 585 postmenopausal women with osteoporosis who did not use osteoporosis medications were retrospectively reviewed. 290 patients were administered 60 mg DEN subcutaneously every 6 months from 2017 to 2018, and 295 patients were treated with 5 mg ZOL intravenously yearly from 2015 to 2017. BMD, TBS, and C-terminal cross-linking telopeptide of type 1 collagen (CTX) measurements were obtained at baseline and two-year after DEN injection or ZOL infusion. RESULTS After two-year follow-up, 188 patients in the DEN group and 183 patients in the ZOL group were compared. BMD change from baseline at two years was significantly greater in the DEN group compared with the ZOL group (P < 0.001). The changes of TBS in the DEN group were statistically significant compared with baseline (P < 0.001) and the ZOL group (P < 0.001). The DEN group led to significantly greater reduction of CTX compared with ZOL group (P = 0.041). CONCLUSION In postmenopausal women with osteoporosis, DEN was associated with greater BMD increase at all measured skeletal sites, greater increase of TBS, and greater inhibition of bone remodeling compared with ZOL.
Collapse
Affiliation(s)
- Taewook Kang
- Department of Orthopedics, Anam Hospital, Korea University School of Medicine, Seoul, Korea
| | - Si Young Park
- Department of Orthopedics, Anam Hospital, Korea University School of Medicine, Seoul, Korea.
| | - Soon Hyuck Lee
- Department of Orthopedics, Anam Hospital, Korea University School of Medicine, Seoul, Korea
| | - Jong Hoon Park
- Department of Orthopedics, Anam Hospital, Korea University School of Medicine, Seoul, Korea
| | - Seung Woo Suh
- Department of Orthopedics, Anam Hospital, Korea University School of Medicine, Seoul, Korea
| |
Collapse
|
39
|
Hung C, Mathews KD, Shibli-Rahhal A. Effect of Denosumab on Bone Health in Adult Patients with Duchenne/Becker Muscular Dystrophy: A Report of 2 Cases. JBJS Case Connect 2022; 12:01709767-202203000-00071. [PMID: 35294424 DOI: 10.2106/jbjs.cc.21.00664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
CASE Duchenne/Becker muscular dystrophy (DMD/BeMD) is caused by a loss of dystrophin leading to muscular weakness. Glucocorticoids are used to delay loss of muscle strength but frequently result in osteoporosis and fractures. Bisphosphonates are the drug of choice, and there are limited data on the efficacy of denosumab. We describe 2 patients who were treated with denosumab and had stable to improved bone density with no side effects. CONCLUSION Denosumab can be considered for the treatment of osteoporosis in adults with DMD/BeMD, especially when the response to bisphosphonates is not satisfactory.
Collapse
Affiliation(s)
- Chermaine Hung
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa
| | - Katherine D Mathews
- Department of Neurology, University of Iowa, Iowa City, Iowa.,Department of Pediatrics, University of Iowa, Iowa City, Iowa
| | | |
Collapse
|
40
|
Wawrzyniak A, Skrzypczak-Zielińska M, Michalak M, Kaczmarek-Ryś M, Ratajczak AE, Rychter AM, Skoracka K, Marcinkowska M, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis? Front Endocrinol (Lausanne) 2022; 13:1063762. [PMID: 36714573 PMCID: PMC9880251 DOI: 10.3389/fendo.2022.1063762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 12/21/2022] [Indexed: 01/15/2023] Open
Abstract
INTRODUCTION One of the challenges of personalized medicine is a departure from traditional pharmacology toward individualized, genotype-based therapies. Postmenopausal osteoporosis is a prevalent condition requiring intensive treatment, whose effects are measurable only after a long time, and the goal is bone fracture prevention. This study aimed to determine the influence of VDR gene variation on anti-osteoporotic one-year treatment with denosumab in 63 Polish women with postmenopausal osteoporosis. MATERIALS AND METHODS The correlation between bone mineral density (BMD) of the lumbar vertebral column (L1-L4) and femoral neck, and genotype distributions for the ApaI, BsmI, FokI, and TaqI variants of the VDR gene was analyzed. Bone fractures during denosumab therapy were also investigated. RESULTS In the case of the Bsml polymorphism, female patients with BB and Bb genotypes had statistically significantly higher values of BMD and T-score/Z-score indicators, which persisted after a year of denosumab treatment. Our results indicated that the Bsml polymorphism contributes to better bone status, and, consequently, to more efficient biological therapy. The study did not reveal significant differences between changes (delta) in BMD and genotypes for the analyzed VDR gene loci. In the entire study group, one bone fracture was observed in one patient throughout the yearlong period of denosumab therapy. CONCLUSIONS BB and Bb genotypes of the Bsml polymorphism of the VDR gene determine higher DXA parameter values both before and after one-year denosumab therapy in postmenopausal women with osteoporosis.
Collapse
Affiliation(s)
- Anna Wawrzyniak
- Department of Family Medicine, Poznan University of Medical Sciences, Poznań, Poland
| | | | - Michał Michalak
- Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznań, Poland
| | | | - Alicja Ewa Ratajczak
- Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland
- Doctoral School, Poznan University of Medical Sciences, Poznań, Poland
- *Correspondence: Alicja Ewa Ratajczak,
| | - Anna Maria Rychter
- Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland
- Doctoral School, Poznan University of Medical Sciences, Poznań, Poland
| | - Kinga Skoracka
- Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland
- Doctoral School, Poznan University of Medical Sciences, Poznań, Poland
| | | | - Ryszard Słomski
- Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland
| | - Agnieszka Dobrowolska
- Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland
| | - Iwona Krela-Kaźmierczak
- Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland
| |
Collapse
|
41
|
Boschitsch E, Naegele O, Klinger A, Brix-Samoylenko H. Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis. Osteoporos Int 2022; 33:263-272. [PMID: 34432114 DOI: 10.1007/s00198-021-06102-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 08/16/2021] [Indexed: 12/25/2022]
Abstract
UNLABELLED In short-term studies, persistence with denosumab has been higher than with other osteoporosis drugs. This study shows that persistence can be maintained in the long-term and is associated with efficacy and safety parameters. PURPOSE To assess long-term persistence with denosumab in postmenopausal women with osteoporosis. Secondary purposes were the evaluation of changes in efficacy and tolerance/safety parameters over time. METHODS Persistence was determined by number and rate of patients receiving denosumab on time in 6-month intervals (+ / - 8 weeks). The total population was stratified by internal patients (injections and monitoring at the Austrian Osteoporosis Clinic [AOC], 74%) and external patients (injections at the practitioner's office with occasional monitoring at the AOC, 26%). In internal patients, efficacy parameters including bone mineral density (BMD) and the bone marker CTX were assessed at fixed time points and tolerance/safety parameters including side effects (SEs), adverse events (AEs), and serious AEs (SAEs) evaluated. RESULTS Of 851 patients, 71% (73% internal and 64% external) were persistent at 7.5 years of follow-up. The mean rate of cumulative persistence in internal patients decreased from 94% at the time of the second dose to 73% at the time of the fifteenth dose. BMD increased and CTX decreased, overall and in pairwise comparisons (all p < .001). AEs and SAEs, but not SEs, were lower in persistent than non-persistent patients. CONCLUSIONS This is the first study showing that long-term (> 3 years) real-world persistence with denosumab could be maintained at a high level (> 70%) in most patients. Denosumab was well tolerated and associated with decreased CTX levels and increased BMD.
Collapse
Affiliation(s)
- Ewald Boschitsch
- Austrian Osteoporosis Clinic (AOC), Vienna, Austria.
- KLIMAX Menopause and Osteoporosis Clinic, Vienna, Austria.
| | - Oliver Naegele
- KLIMAX Menopause and Osteoporosis Clinic, Vienna, Austria
| | - Anita Klinger
- Austrian Osteoporosis Clinic (AOC), Vienna, Austria
- KLIMAX Menopause and Osteoporosis Clinic, Vienna, Austria
| | | |
Collapse
|
42
|
Davis S, Simpson E, Hamilton J, James MMS, Rawdin A, Wong R, Goka E, Gittoes N, Selby P. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 2021; 24:1-314. [PMID: 32588816 DOI: 10.3310/hta24290] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia®; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista®; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity®; Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and Amgen Inc.] and teriparatide [Forsteo®; Eli Lilly and Company, Indianapolis, IN, USA]}, compared with each other, bisphosphonates or no treatment, for the prevention of fragility fracture. DATA SOURCES For the clinical effectiveness review, nine electronic databases (including MEDLINE, EMBASE and the World Health Organization International Clinical Trials Registry Platform) were searched up to July 2018. REVIEW METHODS A systematic review and network meta-analysis of fracture and femoral neck bone mineral density were conducted. A review of published economic analyses was undertaken and a model previously used to evaluate bisphosphonates was adapted. Discrete event simulation was used to estimate lifetime costs and quality-adjusted life-years for a simulated cohort of patients with heterogeneous characteristics. This was done for each non-bisphosphonate treatment, a strategy of no treatment, and the five bisphosphonate treatments previously evaluated. The model was populated with effectiveness evidence from the systematic review and network meta-analysis. All other parameters were estimated from published sources. An NHS and Personal Social Services perspective was taken, and costs and benefits were discounted at 3.5% per annum. Fracture risk was estimated from patient characteristics using the QFracture® (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK) and FRAX® (web version 3.9, University of Sheffield, Sheffield, UK) tools. The relationship between fracture risk and incremental net monetary benefit was estimated using non-parametric regression. A probabilistic sensitivity analysis and scenario analyses were used to assess uncertainty. RESULTS Fifty-two randomised controlled trials of non-bisphosphonates were included in the clinical effectiveness systematic review and an additional 51 randomised controlled trials of bisphosphonates were included in the network meta-analysis. All treatments had beneficial effects compared with placebo for vertebral, non-vertebral and hip fractures, with hazard ratios varying from 0.23 to 0.94, depending on treatment and fracture type. The effects on vertebral fractures and the percentage change in bone mineral density were statistically significant for all treatments. The rate of serious adverse events varied across trials (0-33%), with most between-group differences not being statistically significant for comparisons with placebo/no active treatment, non-bisphosphonates or bisphosphonates. The incremental cost-effectiveness ratios were > £20,000 per quality-adjusted life-year for all non-bisphosphonate interventions compared with no treatment across the range of QFracture and FRAX scores expected in the population eligible for fracture risk assessment. The incremental cost-effectiveness ratio for denosumab may fall below £30,000 per quality-adjusted life-year at very high levels of risk or for high-risk patients with specific characteristics. Raloxifene was dominated by no treatment (resulted in fewer quality-adjusted life-years) in most risk categories. LIMITATIONS The incremental cost-effectiveness ratios are uncertain for very high-risk patients. CONCLUSIONS Non-bisphosphonates are effective in preventing fragility fractures, but the incremental cost-effectiveness ratios are generally greater than the commonly applied threshold of £20,000-30,000 per quality-adjusted life-year. STUDY REGISTRATION This study is registered as PROSPERO CRD42018107651. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 29. See the NIHR Journals Library website for further project information.
Collapse
Affiliation(s)
- Sarah Davis
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Emma Simpson
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Jean Hamilton
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Marrissa Martyn-St James
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Andrew Rawdin
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Ruth Wong
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Edward Goka
- Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
| | - Neil Gittoes
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | - Peter Selby
- School of Medical Sciences, University of Manchester, Manchester, UK
| |
Collapse
|
43
|
Nakamura Y, Shimizu T, Asano T, Shimodan S, Ishizu H, Takahashi D, Takahata M, Iwasaki N. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis. J Bone Miner Metab 2021; 39:824-832. [PMID: 33821302 PMCID: PMC8021003 DOI: 10.1007/s00774-021-01221-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 03/04/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION We aimed to compare the efficacy after switching from either bisphosphonates (BPs) or non-BPs (NBPs) to combination therapies of denosumab (DMAb) or zoledronic acid (Zol) with eldecalcitol (ELD) in bone mineral density (BMD) and bone metabolism and investigate the prognostic and risk factors of side effects of this therapy. MATERIALS AND METHODS One-hundred forty-eight patients with postmenopausal osteoporosis were recruited; their therapy was switched from BPs or NBPs to Zol or DMAb plus ELD (BP-Zol: 43, NBP-Zol: 32, BP-DMAb: 35, and NBP-DMAb: 38). Longitudinal changes in bone metabolic markers (P1NP and TRACP-5b) and BMD were evaluated. RESULTS In the BP-Zol group, P1NP did not change after 6 months and increased by 38.9% after 12 months. TRACP-5b decreased 15.8% after 6 months, but came back to baseline values 12 months after administration. In the rest of the groups, the bone metabolic markers remained suppressed after 6 and 12 months. Compared with baseline, all groups showed increase in BMD after 6 and 12 months. Bone metabolic markers at baseline were correlated with %change in lumbar spine BMD from baseline to 12 months. P1NP and 25-hydroxy vitamin D levels at baseline were identified as potential predictors of development of acute-phase reactions. CONCLUSIONS The combination therapy of Zol or DMAb and ELD may increase BMD at 12 months after the first administration in Japanese patients with postmenopausal osteoporosis, regardless of BPs pretreatment. Bone metabolic markers at baseline may be useful predictors for reaction to the therapy and side effects caused by these combination therapies in postmenopausal osteoporosis.
Collapse
Affiliation(s)
- Yumejiro Nakamura
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Tomohiro Shimizu
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
| | - Tsuyoshi Asano
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Shun Shimodan
- Department of Orthopaedic Surgery, Kushiro City General Hospital, Kushiro, Japan
| | - Hotaka Ishizu
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
- Department of Orthopaedic Surgery, Kushiro City General Hospital, Kushiro, Japan
| | - Daisuke Takahashi
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Masahiko Takahata
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Norimasa Iwasaki
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| |
Collapse
|
44
|
Ishizu H, Arita K, Terkawi MA, Shimizu T, Iwasaki N. Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis. Expert Rev Endocrinol Metab 2021; 16:217-228. [PMID: 34310233 DOI: 10.1080/17446651.2021.1956902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 07/14/2021] [Indexed: 10/20/2022]
Abstract
Introduction: Osteoporosis is characterized by the fragility of bones, leading to fractures and, consequently, the deterioration of functional capacity and quality of life. Postmenopausal women, in particular, are prone to osteoporosis and often require anti-osteoporosis treatment. In the last few decades, various anti-osteoporosis drugs have been approved for clinical use. In an aging society, osteoporosis cannot be treated using a single agent; therefore, switching therapy is an important treatment strategy.Areas covered: This review covers switching therapy in patients with postmenopausal osteoporosis. It's extremely important to understand the characteristics of each drug including; limitations on the duration of use, side effects due to long-term use (such as atypical femur fracture and osteonecrosis of the jaw) or discontinuation (such as rebound phenomenon), compliance, and ability to prevent fractures. We review and summarize the risks and benefits of switching therapy.Expert opinion: When switching therapy, the order of drug administration is important. Routine monitoring should be continued after switching treatments. We recommend first using osteoanabolic agents in postmenopausal women with severe osteoporosis. In addition, identifying predictors of the efficacy and side effects of treatment may help prevent the inappropriate use of drugs for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Hotaka Ishizu
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo, Japan
| | - Kosuke Arita
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo, Japan
| | - Mohamad Alaa Terkawi
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo, Japan
| | - Tomohiro Shimizu
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo, Japan
| | - Norimasa Iwasaki
- Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo, Japan
| |
Collapse
|
45
|
Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 2021; 16:533. [PMID: 34452621 PMCID: PMC8393477 DOI: 10.1186/s13018-021-02678-x] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 08/16/2021] [Indexed: 12/24/2022] Open
Abstract
Background Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality. This Bayesian network meta-analysis compared the effects of current anti-osteoporosis drugs on bone mineral density. Methods The present systematic review and network meta-analysis follows the PRISMA extension statement to report systematic reviews incorporating network meta-analyses of health care interventions. The literature search was performed in June 2021. All randomised clinical trials that have investigated the effects of two or more drug treatments on BMD for postmenopausal osteoporosis were accessed. The network comparisons were performed through the STATA Software/MP routine for Bayesian hierarchical random-effects model analysis. The inverse variance method with standardised mean difference (SMD) was used for analysis. Results Data from 64 RCTs involving 82,732 patients were retrieved. The mean follow-up was 29.7 ± 19.6 months. Denosumab resulted in a higher spine BMD (SMD −0.220; SE 3.379), followed by pamidronate (SMD −5.662; SE 2.635) and zoledronate (SMD −10.701; SE 2.871). Denosumab resulted in a higher hip BMD (SMD −0.256; SE 3.184), followed by alendronate (SMD −17.032; SE 3.191) and ibandronate (SMD −17.250; SE 2.264). Denosumab resulted in a higher femur BMD (SMD 0.097; SE 2.091), followed by alendronate (SMD −16.030; SE 1.702) and ibandronate (SMD −17.000; SE 1.679). Conclusion Denosumab results in higher spine BMD in selected women with postmenopausal osteoporosis. Denosumab had the highest influence on hip and femur BMD. Level of evidence Level I, Bayesian network meta-analysis of RCTs
Collapse
Affiliation(s)
- Filippo Migliorini
- Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
| | - Nicola Maffulli
- Department of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi, Salerno, Italy.,Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, 275 Bancroft Road, London, E1 4DG, England.,School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Thornburrow Drive, Stoke on Trent, England
| | - Giorgia Colarossi
- Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany
| | - Jörg Eschweiler
- Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany
| | - Markus Tingart
- Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany
| | - Marcel Betsch
- Department of Orthopaedics and Trauma Surgery, University Hospital Mannheim, Medical Faculty of the University Heidelberg, Mannheim, Germany
| |
Collapse
|
46
|
Laura I, Felicia B, Alexia C, Aude M, Florence B, Murielle S, Rafik K, Jean-Jacques B, Pierre B. Which treatment to prevent an imminent fracture? Bone Rep 2021; 15:101105. [PMID: 34386562 PMCID: PMC8342786 DOI: 10.1016/j.bonr.2021.101105] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 06/28/2021] [Accepted: 07/02/2021] [Indexed: 11/11/2022] Open
Abstract
Purpose To provide a summarized state of the art of the relative efficacy and rapidity of action of pharmacological treatments to prevent imminent osteoporotic fractures. Methods We reviewed metanalyses (MA) and network metaanalyses (NMA) published during the last 10 years concerning the pharmacological treatment of osteoporosis. We compared the anti-fracture efficacy and the rapidity of action of various agents versus placebo and versus risedronate. Results All bisphosphonates decrease the incidence of vertebral fractures compared with placebo. Ibandronate is the only one without demonstrated efficacy against non-vertebral and hip fractures. Zoledronate, denosumab and anabolic therapy are associated with a higher fracture risk reduction than oral bisphosphonates. Compared with risedronate, which significantly reduces the rate of hip fractures, zoledronate, denosumab, teriparatide, abaloparatide and romosozumab are more efficient for vertebral fractures but not for non-vertebral or hip fractures reduction. No studies have compared bone anabolic treatments with zoledronate or denosumab. Oral bisphosphonates significantly reduce fracture risk only after more than one year of therapy. A faster reduction of fracture risk is observed with zoledronate and denosumab, or with anabolic agents. For denosumab and anabolic agents, a sequential treatment is required to keep gains after treatment withdrawal. Conclusions In patients at high risk of imminent fracture, starting therapy with potent antiresorptive agents or with an anabolic agent seems most appropriate to promptly reduce the fracture risk. Available NMA/MA suggest that, compared to zoledronate and denosumab, anabolic agents have a higher efficacy for vertebral fractures but head-to-head studies are lacking. The concept of imminent fracture has implications for the choice of therapy We reviewed metanalyses and network metaanalyses published in the last 10 years We compared the efficacy and rapidity of treatments to prevent imminent fractures Potent antiresorptive and anabolic agents are most appropriate to promptly reduce fracture risk Anabolic agents seem to be more efficient to reduce vertebral fracture risk
Collapse
Affiliation(s)
- Iconaru Laura
- Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Baleanu Felicia
- Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Charles Alexia
- Laboratoire de Recherche Translationnelle, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Mugisha Aude
- Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Benoit Florence
- Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Surquin Murielle
- Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Karmali Rafik
- Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Body Jean-Jacques
- Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.,Laboratoire de Recherche Translationnelle, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.,Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - Bergmann Pierre
- Laboratoire de Recherche Translationnelle, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.,Department of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
47
|
Diebo BG, Sheikh B, Freilich M, Shah NV, Redfern JAI, Tarabichi S, Shepherd EM, Lafage R, Passias PG, Najjar S, Schwab FJ, Lafage V, Paulino CB. Osteoporosis and Spine Surgery: A Critical Analysis Review. JBJS Rev 2021; 8:e0160. [PMID: 33006455 DOI: 10.2106/jbjs.rvw.19.00160] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Despite being part of the aging process, early and adequate management of osteoporosis mitigates adverse outcomes associated with low bone mineral density. Although the health-care burden of osteoporosis is on the rise, screening and management of osteoporosis are not yet an integral part of preoperative patient evaluation in spine surgery. Patients with osteoporosis should undergo multidisciplinary evaluation and management, including lifestyle modifications and initiation of multiple therapeutic modalities. Integrating osteoporosis in preoperative optimization and surgical planning for patients undergoing spine surgery has the potential to mitigate osteoporosis-related postoperative complications.
Collapse
Affiliation(s)
- Bassel G Diebo
- 1Department of Orthopaedic Surgery and Rehabilitation Medicine, State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York 2Royal College of Surgeons in Ireland (RCSI)-Bahrain, Al Sayh, Bahrain 3Division of Spine Surgery, Methodist Hospitals, Merrillville, Indiana 4Spine Service, Hospital for Special Surgery, New York, NY 5Department of Orthopaedic Surgery, NYU Langone Orthopedic Hospital, New York, NY 6Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Atsumi T, Miyoshi H. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis. J Diabetes Investig 2021; 12:1293-1300. [PMID: 33141482 PMCID: PMC8264394 DOI: 10.1111/jdi.13458] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 10/05/2020] [Accepted: 10/26/2020] [Indexed: 01/22/2023] Open
Abstract
AIMS/INTRODUCTION Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has not been elucidated. In this study, we investigated the effects of switching to Dmab from bisphosphonates (BP) or a selective estrogen receptor modulator (SERM) in postmenopausal type 2 diabetes mellitus patients. MATERIALS AND METHODS This was a three medical institutions, prospective, observational study for postmenopausal patients with type 2 diabetes mellitus whose T-score of femoral neck or lumbar spine bone mineral density was under -1.0 standard deviation, even after >6 months of BP or SERM administration. After obtaining consent, participants were treated for osteopenia/osteoporosis by either continuing BP (BP-BP group)/SERM (SERM-SERM group), or by switching to Dmab (BP-Dmab or SERM-Dmab groups). Changes in bone mineral density and bone metabolism marker levels were evaluated after 6 months. RESULTS A total of 48 patients were included in this study, and each group comprised 12 patients. No significant difference existed in baseline characteristics among the groups. The average age and glycated hemoglobin were 71 ± 8 years and 7.2 ± 0.9%, respectively. In the SERM-Dmab group, lumbar spine bone mineral density was significantly increased by 5.0% compared with the SERM-SERM group (P < 0.04). Serum bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase 5b were significantly decreased in the BP-Dmab and SERM-Dmab groups compared with the BP-BP and SERM-SERM groups, respectively. CONCLUSIONS Switching to Dmab from BP or SERM is beneficial to prevent osteoporosis progression in postmenopausal patients with type 2 diabetes mellitus patients.
Collapse
Affiliation(s)
- Arina Miyoshi
- Department of Diabetes and EndocrinologySapporo City General HospitalSapporoJapan
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Hiraku Kameda
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - So Nagai
- Sapporo Medical Center NTT ECSapporoJapan
| | - Akinobu Nakamura
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Aika Miya
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Takahiro Takase
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Tatsuya Atsumi
- Department of Rheumatology, Endocrinology and NephrologyFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Hideaki Miyoshi
- Division of Diabetes and ObesityFaculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
| |
Collapse
|
49
|
Abstract
Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.
Collapse
Affiliation(s)
- Jacques P Brown
- Division of Rheumatology, Department of Medicine, Laval University, Quebec City, QC, Canada
| |
Collapse
|
50
|
Zeytinoglu M, Naaman SC, Dickens LT. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis. Endocrinol Metab Clin North Am 2021; 50:205-222. [PMID: 34023039 DOI: 10.1016/j.ecl.2021.03.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Denosumab (DMAB) is a potent antiresorptive treatment used for treatment of osteoporosis and low bone mineral density (BMD) in those at high risk for fracture. In postmenopausal women with osteoporosis, DMAB treatment for 10 years has been studied, with results showing continued gains in BMD, sustained fracture risk reduction, and low risk of adverse events. However, upon discontinuation of DMAB, there is a rapid reversal of effect, with increase in bone turnover, loss of BMD, and in a subset of patients, a greater risk for multiple vertebral fractures.
Collapse
Affiliation(s)
- Meltem Zeytinoglu
- Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, AMB M267, Chicago, IL 60637, USA.
| | - Sandra C Naaman
- Section of General Internal Medicine, Department of Medicine, University of Chicago, 355 East Grand Street, Chicago, IL 60611, USA
| | - Laura T Dickens
- Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, AMB M267, Chicago, IL 60637, USA
| |
Collapse
|